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ABSTRACT
IDENTIFYING REGULATORS FROM MULTIPLE TYPES OF BIOLOGICAL DATA IN
CANCER

Brittany Baur
Marquette University, 2017

Cancer genomes accumulate alterations that promote cancer cell proliferation and survival.
Structural, genetic and epigenetic alterations that have a selective advantage for tumorigenesis
affect key regulatory genes and microRNAs that in turn regulate the expression of many target
genes. The goal of this dissertation is to leverage the alteration-rich landscape of cancer genomes
to detect key regulatory genes and microRNAs. To this end, we designed a feature selection
algorithm to identify DNA methylation signals around a gene that would highly predict its
expression. We found that genes whose expression could be predicted by DNA methylation
accurately were enriched in Gene Ontology terms related to the regulation of various biological
processes. This suggests that genes controlled by DNA methylation are regulatory genes. We also
developed two tools that infer relationships between regulatory genes and target genes leveraging
structural and epigenetic data. The first tool, ProcessDriver integrates copy number alteration and
gene expression datasets to identify copy number cancer driver genes, target genes of these drivers
and the disrupted biological processes. Our results showed that driver genes selected by
ProcessDriver are enriched in known cancer genes. Using survival analysis, we showed that drivers
are linked to new tumor events after initial treatment. The second tool was developed to leverage
structural and epigenetic data to infer interactions between regulatory genes and targets on a
network-level. Our canonical correlation analysis-based approach utilized the DNA methylation or
copy number states of potential regulators and the expression states of potential targets to score
regulatory interactions. We then incorporated these regulatory interaction scores as prior
knowledge in a dynamic Bayesian framework utilizing time series gene expression data. Our results
indicated that the canonical correlation analysis-based scores reflect the true interactions between
genes with high accuracy, and the accuracy can be further increased by using the scores as a prior
in the dynamic Bayesian framework. Finally, we are developing an algorithm to detect cancerrelated microRNAs, associated targets and disrupted biological processes. Our preliminary results
suggest that the modules of miRNAs and target genes identified in this approach are enriched in
known microRNA-gene interactions.
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CHAPTER 1

Introduction

1.1. Biological background

This section defines the biological background and terms that will be used throughout
this dissertation.
1.1.1. Copy number aberration

Copy number refers to the number of copies of a gene. Typically, there are two copies of
each gene in a diploid genome, one from each parent. Copy number variation (CNV) is a
structural variation in the copy number between human individuals (Henrichsen et al., 2009).
CNVs arise from germline cells and are therefore present in all the cells of the organism (Li et al.,
2009). CNVs are present in healthy individuals and are responsible for phenotypic variation in
humans, but can also cause diseases (Feuk et al., 2006; Henrichsen et al., 2009).
Copy number aberrations or alterations (CNAs) in cancer are somatic changes to copy
number that are only present in the tumor (Li et al., 2009). Amplifications will usually lead to an
increase in expression of genes within the region that is amplified (Lu et al., 2011). Deletions will
usually decrease the expression of genes within the deleted region (Lu et al., 2011). More recently
it has been shown that aberrations of regulatory elements can also alter gene expression
(Beroukhim et al., 2017). For example, enhancer amplification or a deletion of an insulator
element can increase the expression of adjacent genes (Beroukhim et al., 2017). In addition, longrange chromosomal rearrangements and aberrations that place genes closer to enhancers can also
alter expression (Beroukhim et al., 2017). CNAs that recurrent in cancer patients generally harbor
“driver” genes that confer a fitness advantage for tumorigenesis (Akavia et al.,2010). There is a
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positive selection for driver genes that promote cancer cell proliferation and survival in tumors
(Akavia et al., 2010).

1.1.2. Epigenetic variation

Epigenetics refers to non-genetic influences on gene expression. In other words, gene
expression can be altered without a change in the DNA sequence. This dissertation focuses on
DNA methylation. DNA methylation is a chemical change to DNA, in which a methyl group is
added to the nucleotide cytosine. Heritable DNA methylation of cytosine occurs at a CpG site
(Schübeler, 2014). A CpG site is where a cytosine nucleotide is linked to a guanine nucleotide by
a single phosphate in the 5’ to 3’ direction. Approximately, 60% to 90% of CpGs are methylated
in human (Tucker, 2001). When CpG sites are clustered together, it is known as a CpG island.
The effect of DNA methylation on gene expression is dependent on the genomic position
and CpG island status of the DNA methylation. DNA methylation in promoter regions near the
transcription start site (TSS) will lead to a decrease in gene expression, regardless of whether the
DNA methylation is in a CpG island (Varley et al., 2013). However, DNA methylation in the
gene body, farther away from the TSS, could increase or decrease gene expression depending on
whether it is in a CpG island (Varley et al., 2013). DNA methylation in a gene body and not in a
CpG island typically increases gene expression. However, if the DNA methylation occurs inside a
CpG island, it could increase or decrease gene expression (Varley et al., 2013). DNA methylation
of the first exon and near the TSS is tightly linked to decreases in gene expression (Brenet et al.,
2011).
CpG islands are present in approximately 70% of mammalian promoters (Dawson and
Kouzarides, 2012). Approximately 5 to 10% of promoter CpG islands are hypermethylated in
cancer (Dawson and Kouzarides, 2012). Although hypermethylation of promoters is widely
studied in cancer, DNA methylation of the gene bodies may activate oncogenes and could be a
therapeutic target in cancer (Yang et al., 2014).
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1.1.3. microRNAs
microRNAs (miRNAs) are small (~22 nucleotides long), non-coding molecules of RNA
(Ambros, 2004). Pre-miRNAs are produced from non-coding DNA, and then is exported to the
cytoplasm where it is processed into a mature miRNA (Lima et al., 2011). miRNAs decrease
gene expression by base-pairing with complementary mRNA transcripts (Lima et al., 2011). If the
miRNA base-pairs with the mRNA transcript with complete complementarity, the mRNA
transcript will be cleaved (Lima et al., 2011). If the miRNA base-pairs with partial
complementarity, translation of the mRNA transcript into a protein will be repressed or the
mRNA transcript will be destabilized (Lima et al., 2011). In all cases, the translation of a mRNA
transcript into a functional protein is prevented. miRNAs can target many genes and a gene could
be targeted by multiple miRNAs.
miRNAs are largely down-expressed in tumors relative to normal tissue (Di Leva et al.,
2014). Several studies have shown the loss of Dicer1, which is involved in the maturation of
miRNAs, promotes tumorigenesis (Kumar et al., 2009; Lambertz et al., 2009). These results
suggest that miRNAs have mostly tumor suppressor properties, however there are several upexpressed oncomiRNAs in cancer (Di Leva et al., 2014).

1.1.4. Cancer genomes

Genome instability is defined as a high frequency of mutations, such as chromosomal
rearrangements, copy number variations and nucleotide changes (Vincent et al., 2014). During
normal cell generation, the rates of spontaneous mutations are very low due to “caretaker” genes
that resolve defects in DNA replication (Hanahan and Weinberg, 2011). These genes behave as
tumor suppressors as their functions can be lost by epigenetic repression or copy number
deletions, which can lead to an increased mutation rate and in turn increase the risk of tumor
progression (Hanahan and Weinberg, 2011). Structural and epigenetic changes occur randomly,
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but can by chance affect cancer genes, such as these “caretaker” genes, other tumor suppressors
and oncogenes (Stratton, 2011).
Structural and epigenetic changes are inherited over the course of mitotic cell division,
allowing deleterious alterations that undermine genome integrity to accumulate and increase the
proliferation and invasiveness of cancer cells (Jones and Baylin, 2007; Hanahan and Weinberg,
2011). Epigenetic changes may collaborate with structural changes to evolve cancer cells (Jones
and Baylin, 2007). Alterations that promote cell proliferation of the cancer cell have a positive
selective advantage in cancer and therefore deleterious alterations are often recurrent in cancer
patients (Hanahan and Weinberg, 2011). miRNA genes have often been found to be located at
fragile sites of the genome that are prone to alteration, indicating a causative role of miRNAs in
cancer progression, as well (Vincent et al., 2014).

1.2. Statement of problem

In 2016, 1.7 million new cancer cases and 595,690 cancer-related deaths were projected
to occur in the US (Siegel et al., 2016). Cancer genomes accumulate alterations that confer a
fitness advantage for cancer proliferation and survival. These alterations can include copy number
amplifications and deletions, aberrant DNA methylation and changes in the expression of
microRNAs (miRNAs) compared to non-cancer tissue. The genes and miRNAs that are directly
affected by these alterations promote tumorigenesis, and drastically alter the cellular phenotype.
These are key regulatory genes and miRNAs that when disrupted, alter the expression of many
downstream target genes. Recent technology can generate vast amounts of biological data on the
entire genome. Therefore, it is important to gain meaningful information about cancer through
high-throughput biological datasets.
The overall goal of this dissertation is to leverage structural, epigenetic and miRNA
alterations in the cancer genome to identify key regulators that are disrupted by these alterations
and their associated targets by integrating multiple types of biological data. To this end, we have
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developed several algorithms to address the aims of this dissertation. The following is an
overview of the aims that are addressed this dissertation.

1.2.1. Select regions of a gene in which DNA methylation is predictive of its expression

Cancer tissue can exhibit DNA methylation that is too high or too low in critical genes
compared to normal tissue (Akhavan-Niaki and Samadani, 2013). Hypermethylation of CpG
islands in a gene’s promoter in cancer is a typical feature in many cancer genomes (Jones and
Baylin, 2007). This type of hypermethylation generally leads to a decrease in the expression of
tumor supressors. For example, hypermethlation of the promoter of tumor suppressor genes
ITIH5, DKK3 and RASSF1A are biomarkers of breast cancer (Kloten et al., 2013). Since
hypermethylation of the promoter usually decreases gene expression, these tumor suppressors are
less expressed which in turn allow the tumor to proliferate. Hypomethylation is also a
phenomenon in cancer and plays an important role in tumor progression. For example,
hypomethylation of Wnt5a, a signaling protein that influences the expression of many other
genes, could make the gene more accessible for up-expression and promote aggressiveness in
prostate cancer (Wang et al., 2007). Hypomethylation of oncogenes, such as cMYC and H-RAS,
may also make them more accessible for upregulation (Akhavan-Niaki and Samadani, 2013).
There are several next-generation sequencing-based assays to measure DNA methylation
such as bisulfite sequencing (Chatterjee et al.,2011), MeDIP-seq (Down et al., 2008), and reduced
representation bisulfite sequencing (Gu et al., 2011). There are also bisulfite microarray-based
assays to measure DNA methylation (Adorján et al., 2002). For humans, the Illumina Infinium
HumanMethylation27 BeadChip Kit array contains 27,578 probes for 14,495 genes
(Weisenberger et al., 2008). Later, Illumina developed higher-resolution Illumina Infinium
HumanMethylation450 BeadChip Kit array, which have an average of 18 probes associated with
a gene in various genomic positions and CpG island statuses (Bibikova et al., 2011). Due to its
high resolution and low cost, the Illumina Infinium HumanMethylation 450K array has become
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one of the most frequently used assays to quantify DNA methylation in human. At the time of
writing, the Gene Expression Omnibus database (Barrett et al., 2013) had about 30,000 samples
that were profiled using the Illumina 450K array.
Choosing representative DNA methylation probes is important for downstream functional
analysis, such as determining if a gene has aberrant DNA methylation in cancer (Maeda et al.,
2014). DNA methylation probes that are predictive of gene expression may be closer to a
functional region of interest. For example, Rhee et al. found that genes that were down-expressed
and had hypermethylation in the TSS contain sequences for transcription factor binding (Rhee et
al., 2013). Selecting one or two representative probes is also important for predictive models that
may integrate other sources of biological data. For example, Li et al. tested various feature
selection methods to predict whether a gene is up or down expressed in lung cancer based on
DNA methylation and histone features (Li et al., 2015). Using the 450K DNA methylation data,
the authors averaged the DNA methylation probes in genomic regions, such as the gene body.
The drawback of averaging the value at each probe is that signals can be lost. An alternative
approach would be to utilize the most representative probes as features.
However, it is not straightforward to determine which probes to choose from a 450K
array that best represent the overall methylation level of the gene and are informative to the
gene’s expression level. A simple, but valuable approach may be to choose a single probe based
on a metric such as the variation. One approach is to use the standard deviation (SD) across
samples and choose the probes with the greatest variation (Selamat et al., 2012; Noushmehr et al.,
2010). Other studies restrict the analysis to probes from CpG islands in upstream regions, since
DNA methylation blocking transcription factors from binding is a well-studied phenomenon (Li
et al., 2014). Several studies restrict the number of probes to those within a certain proximity
surrounding the TSS (Farré et al, 2015; Rica et al., 2013). However, both approaches ignore
possibly informative DNA methylation in the gene body.
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Due to the context-dependent nature of DNA methylation, the need to identify the regions
of DNA methylation of interest, and its critical importance to cancer, we proposed an approach
that, for a given gene, selected the most “informative” areas of DNA methylation. In this method,
“informative” was defined by the probe(s) of the gene where DNA methylation was most
predictive of gene expression. Gene expression was binary, indicating whether the sample was
up-expressed or down-expressed when treated with a hypomethylating agent versus untreated for
breast cancer cell line data (Li et al., 2014). We also used up-expressed and down-expressed
samples with respect to the median for the Cancer Genome Atlas (TCGA) luminal A breast
cancer data (The Cancer Genome Atlas, 2012). This approach was designed for the 450K DNA
methylation array, where there is an average of 18 probes per gene.
Multiple classification and feature selection methods to select the most informative DNA
methylation probes for a given gene were evaluated in this aim. Due to the context-dependent
nature of DNA methylation, the feature selection was unsupervised and did not consider genomic
position of the probes or CpG island status of the genome position.

1.2.2. Infer copy number drivers and associated biological processes

A copy number aberration that is recurrent in cancer patients harbors genes that promote
cancer cell proliferation and survival (Hanahan and Weinberg, 2000). There is a positive selection
advantage for an aberration that affects genes that allow the tumor to grow and proliferate. These
genes, which are oncogenes and tumor suppressors, are known as “drivers.” Large aberrations can
also harbor genes that do not have a fitness advantage to tumor proliferation which are known as
“passenger” genes. Passenger genes that do not have a selective advantage are amplified or
deleted along with the drivers due to their proximity to the driver and as a result, have similar
changes in expression with respect to copy number. Due to their similar copy number and
expression profiles, separating drivers from passengers is an important and difficult challenge.
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The goal of this aim is to identify copy number drivers in a large aberration by
associating the driver with downstream disrupted biological processes. We proposed a
computational pipeline, called ProcessDriver, based on the idea that there are driver genes located
within an aberrated region that regulate the expression of genes outside the aberration. Therefore,
an aberration can have effects across the genome extending beyond the region undergoing gains
and losses via the driver genes inside the region. This is because a driver is influential in changing
the pathology of the cell from normal to tumor, and therefore has many target interactions. The
driver gene is the link between the aberration and genes affected by the aberration located
elsewhere in the genome. This idea was leveraged to separate the passengers from drivers.
Additionally, our method is unique in uncovering the biological processes that are driven
by the driver genes. Certain biological processes are known to be disrupted in cancer, such as cell
cycle and cell death (Evan and Vousden, 2001). Aberrations that allow the cell to evade cell death
and undergo cell cycle more frequently are favored in tumors. ProcessDriver associates a driver
with the targets of the biological process(es) that it most likely disrupts.

1.2.3. Infer gene regulatory networks by integrating structural and epigenetic information

One of the challenging and important computational problems in systems biology is to
infer networks of genetic interactions. A gene regulatory network is a graph where nodes
represent genes and edges between the genes represent an interaction. The interaction, for
instance, could be a transcription factor-target relationship. In a directed network, an edge goes
from a regulator to a target. Traditionally, gene expression data are used to detect changes in a
regulator’s expression and examine the corresponding downstream effects on a target’s
expression (Hecker et al., 2009). However, heterogeneous data sources have improved the
inference of gene regulatory networks (Hecker et al., 2009).
The goal of this aim is to infer regulatory networks by integrating copy number and DNA
methylation along with gene expression data. We proposed canonical correlation analysis-based
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approach which utilized the DNA methylation or copy number states of potential regulators and
the expression states of potential targets to score interactions. Our algorithm assumes that
changes to a regulator’s copy number or DNA methylation would lead to downstream changes in
a target’s expression level. Therefore, changes in the DNA methylation or copy number states of
regulators may be seen as a natural perturbation to the regulator that can aid in establishing
directionality in the network. Therefore, this approach may be better than using expression states
for both regulators and targets. Furthermore, we integrated time series gene expression data with
a dynamic Bayesian approach using the scores from our canonical correlation analysis-based
algorithm as prior knowledge.

1.2.4. Infer cancer-related miRNA-gene module drivers

The expression of certain key miRNAs is known to be altered in cancer cells (Lu et al.,
2005). Since miRNAs regulate the expression of genes, changes in the expression of key miRNAs
in cancer could have widespread, downstream effects. A miRNA and its target genes are known
as a “driver module” if the effects of a disruption in miRNA expression, and corresponding
changes in the expression of its target genes, promote cancer cell survival and proliferation.
The goal of this aim is to associate miRNAs with potential targets via biological
processes. Certain biological processes are known to be dysregulated in cancer tumors via
miRNAs, such as apoptosis (Lima et al., 2011) and cell cycle (Kim et al., 2009). If a miRNA is
disrupted in cancer, and the targets genes are involved in one or more of these processes, that
miRNA is more likely to be a driver. Therefore, biological process information could be used to
aid in miRNA-gene module driver detection. To our knowledge, no other approach has associated
a miRNA with target genes via biological processes. Our approach is able to identify likely
miRNA drivers, associated targets and processes that are disrupted as a result of the changes in
expression of the miRNA driver and corresponding target genes.

10
1.3 Status of Problem

1.3.1. Select regions of a gene in which DNA methylation is predictive of gene expression

To our knowledge, there has been no previous algorithm designed to select DNA
methylation probes associated with a gene from the Illumina Infinium 450K DNA methylation
array that are most informative to a gene’s expression level. However, a variety of studies
integrate epigenetic factors to explain gene expression and are outlined here.
Rhee et al. provided an extensive analysis of the effects of DNA methylation on gene
expression in different molecular subtypes of breast cancer (Rhee et al., 2013). They found that
there is more positive correlation of gene expression moving upstream of the TSS in less
aggressive subtypes of breast cancer compared to more aggressive subtypes. This study also used
decision trees to investigate the combinatorial effects of DNA methylation status in different
genomic positions on gene expression and found CpG islands to be the most informative feature.
Li et al. tested various models to predict differential gene expression in normal versus
tumor samples using epigenomics data in lung cancer (Li et al., 2015). The model predicts
whether an individual gene is up- or down-expressed in lung cancer compared to normal tissue
using histone H3 methylation modification, DNA methylation, nucleotide composition and
nucleotide composition based features. They found that a model comprised of 67 features chosen
with a ReliefF feature selection and random forest classification performed the best. Many of the
selected features were related to the CpG methylation status of the promoter suggesting that
promoter methylation is an important predictor of differential expression in normal versus tumor
samples.
Gevaert et al. developed an algorithm called MethylMix which identifies differentially
methylated genes that are predictive of gene expression (Gevaert et al., 2015). MethylMix uses
beta-mixture modeling to identify subpopulations of patients with similar DNA methylation
levels for each CpG site. For a CpG site, each beta mixture represents a subset of patients where a
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particular beta distribution of DNA methylation states is observed. Next, the algorithm
determines which sites are hypo- or hyper-methylated by comparing the mean of each mixture
component of each CpG site with the mean methylation of the normal samples. For hypo- or
hyper-methylated genes, linear regression was used to determine if DNA methylation had a
significant impact on gene expression. Their analysis found that hyper- and hypo-methylated
genes have oncogenic and tumor suppressor properties. For example, they found that tumor
suppressor TMEM25 was hypermethylated in many cancers, and the hypermethylation prevents
gene expression.

1.3.2. Infer copy number drivers and associated biological processes

Many algorithms have been proposed that identify candidate copy number genes. The
problem of computationally separating driver genes that promote tumorigenesis from passenger
genes in a large, aberrated region remains a challenging one. The result of these algorithms is a
list of candidate driver genes in the recurrent aberration, possibly a ranked list with a score. These
lists could be further validated by experimental or computational techniques.
GISTIC2.0 uses segmented copy number data to find regions of the genome that harbor
drivers because they are recurrent in cancer samples (Mermel et al., 2011). Segmented copy
number data describe the copy number of a particular segment of the genome for a given patient.
It could be thought of as a “snapshot” of the copy number at the point in time the data were
obtained. However, the segmented data does not describe the underlying alterations that have
taken place resulting in a particular segmented datum. Different alterations could have taken
place leading up to the “snapshot” value, and alterations can often overlap. Therefore, finding
alterations that are recurrent in cancer samples is a challenge.
GISTIC2.0 deconstructs the segmented copy number profile into a set of likely
alterations, and then finds the alterations that are recurrent over cancer samples. An algorithm
called Ziggurat deconstruction alternates between estimating the background rates of copy
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number alteration and computing the most likely deconstruction for each copy number profile.
The output is the copy number alterations for each cancer sample.
The next step is to define the regions that are undergoing significant alterations. That is to
score regions of the genome according to the probability that the observed set of copy number
alterations within the region would have occurred by chance. Alterations that harbor a driver
gene are likely to be frequently occurring and of higher amplitude, therefore GISTIC2.0’s scoring
of regions take both into account. Higher scores mean that the region is likely not altered by
chance, and is undergoing positive selection because it is harboring a driver. GISTIC2.0’s
handling of segmented copy number made it a popular choice for future work for pipelines
integrating expression data to narrow down the candidate drivers within the regions proposed by
GISTIC2.0.
Several studies have focused on integrating cis gene expression (Tamborero et al., 2013;
Fan et al., 2012; Pickering et al., 2013). Cis genes are genes that are located within the aberration
that would be directly impacted by that aberration. The idea behind these studies is that the cis
gene in which copy number has the greatest influence on its expression is a likely candidate
driver. For example, Oncodrive-CIS predicts likely drives based on copy number impact on gene
expression (Tamborero et al., 2013). For a given gene, a score is calculated for each sample with
an aberration that represents the aberration’s impact on gene expression in the sample when
compared to non-aberrated samples as a reference. The median of these scores is the overall score
for the gene. When compared to a background model, when the overall score is higher, the gene
is likely a copy number driver. Ambatipudi et al. also selected drivers based on copy number’s
impact on cis gene expression in gingivobuccal cancers (Ambatipudi et al., 2012). The strength of
the correlation between cis copy number and gene expression is also used to detect drivers (Fan et
al., 2012; Pickering et al., 2013).
Several other methods associate cis genes with downstream target trans genes. Trans
genes are genes located outside of the aberration. The idea behind these studies is that a copy
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number aberration disrupts a key regulatory cis gene. A regulatory gene will control the
expression of target genes elsewhere in the genome. Therefore, when a key regulatory gene is
disrupted because of an amplification or deletion, it is expected that there are widespread,
downstream affects in trans.
CONEXIC is a computational pipeline that associates a driver cis gene that is disrupted
as a result of the aberration with a module of downstream target genes (Akavia et al., 2010). A
modified version of GISTIC is used to find significant aberrations that are recurrent in cancer
patients. Candidate drivers reside within the regions reported by GISTIC. The next steps in the
process are the single modulator step and the network learning step. In the single modulator step,
each candidate driver gene is associated with a preliminary module of target genes. For a
candidate driver, k-means clustering with k=2 and a normal distribution is used to separate the
high and low expressed samples. The initial clusters are the non-aberrated and aberrated samples.
The resulting boundary between the clusters is the threshold for the target gene expression. The
target gene expression is split into two groups, samples where the driver gene expression is below
a threshold and samples where the driver gene expression is above a threshold. If the split is
significant then the target gene is associated with the driver’s module. Modules have twenty or
more target genes to ensure the candidate driver having a large, widespread effect.
In the network learning step of CONEXIC, a regulation program for each module is
learned. The modules have more than twenty target genes as determined in the previous step.
However, any candidate driver associated with more than twenty target genes is a possible
regulator for the module. Therefore, the regulators associated with a module in the network
learning step do not necessarily have to contain the candidate driver the module was originally
associated with in the previous step. The regulatory program is a regression tree where the
decision nodes are the driver and a query on its expression value. The answer to the query is the
corresponding expression of the module. A driver that best splits the module of target gene
expression into two behaviors is chosen at each step. All possible driver-split value combinations
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are tested. Finally, after the regulation program is learned, genes can be moved of out or into the
module associated with the regulation program if there is an improvement in the score.
Aure et al. proposed a computation pipeline that first identifies in-cis correlated genes
and then identified biological processes that the cis-genes were associated with in trans (Aure et
al., 2013). First, in-cis correlation analysis was performed where a cis gene was selected if its
expression was correlated with its own copy number above a certain threshold with a low false
discovery rate. Next, the in-trans correlation analysis was performed. The correlations between
the expression of a selected cis gene and all other genes were calculated. The trans genes were
ranked by their correlation to a given cis gene and an enrichment score was calculated for each
Gene Ontology (GO) term. The enrichment score was the p-value from a minimum
hypergeometric test. Background simulations were performed to test this enrichment. If the actual
p-value was significant and better than all the p-values from simulations, the in-cis correlated
gene was associated with a GO term in trans. Cis genes that are highly correlated to copy number
and significantly associated with biological processes are potential driver genes.

1.3.3. Infer gene regulatory networks by integrating structural and epigenetic information

Many different methods have been applied to the problem of inferring gene regulatory
networks (Margolin et al., 2006; Husmeier, 2003). Many of the methods are dependent on either
time series or steady state gene expression data (Hecker et al., 2009). One of the most popular
tools, ARACNE, is based on information theory based on steady-state gene expression data
(Margolin et al., 2006). This study defines an edge between genes as an irreducible statistical
dependency between the genes. This statistical dependency is defined as the mutual information
between two genes, which, unlike Pearson correlation, is invariant and non-zero if a dependency
exists. ARACNE has a high true positive rate as well as a high false negative rate.
Dynamic Bayesian network (DBN) is a popular method for inferring gene regulatory
networks from time series data (Husmeier, 2003). First, a Bayesian network is described by a
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graphical structure 𝐺 = (𝑉, 𝐸), where V is the set of vertices and E is the set of directed edges, a
family of conditional probability distributions F and their associated parameters q that together
defines a joint distribution over the random variables (genes) of interest. Let 𝑋1 , 𝑋2 , … , 𝑋𝑛 be a set
of random variables to be nodes in the graph. The joint probability is built on conditional
probabilities based on the parents of 𝑋𝑖 , 𝑝𝑎(𝑋𝑖 ):
𝑛

𝑃(𝑋1 , 𝑋2 , … , 𝑋𝑛 ) = ∏ 𝑃(𝑋𝑖 |𝑝𝑎[𝑋𝑖 ])

(1.1)

𝑖=1

Since the family of conditional probability distributions if fixed, the problem becomes identifying
the associated parameters q and the network model G* by finding:
𝐺 ∗ = 𝑎𝑟𝑔𝑚𝑎𝑥𝐺 (𝑃(𝐺|𝐷))

(1.2)

And by finding the parameters q* that maximize 𝑃(𝑞|𝐷, 𝐺 ∗). That is the maximization of the
structure given the expression data. By applying Bayes rule, the posterior probability is:
𝑃(𝐺|𝐷) =

1
𝑃(𝐷|𝐺)𝑃(𝐺)
𝑍

(1.3)

Where 𝑍 = ∑𝐺 𝑃(𝐷|𝐺)𝑃(𝐺) is a normalization factor and P(G) is the prior. The marginal
likelihood P(D|G) is calculated by integrating out the parameters:
𝑃(𝐷|𝐺) = ∫ 𝑃(𝐷|𝑞, 𝐺)𝑃(𝑞|𝐺)𝑑𝑞

(1.4)

When the conditional probabilities are defined by a linear Gaussian distribution or a multinomial
distribution and the data is complete, this integral is analytically tractable (Husmeier, 2003).
However, multinomial distributions are often preferred because of their ability to capture nonlinear relationships between genes although data discretization often leads to information loss
(Husmeier, 2003).
However, although the integral in Eq. 1.4 can be solved the posterior distribution in Eq.
1.3 is usually intractable. As the number of nodes in the graph increases, the number of potential
graphs also increases which makes an exhaustive search impossible since the denominator in Eq.
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1.3 becomes intractable. Additionally, since the data D is sparse, the data also may not be
represented well by a single G* with the highest posterior probability and may be better
represented by a collection of graphs (Husmeier, 2003). Uncovering the network structure that
maximizes the posterior distribution is only feasible if the posterior distribution is sharply peaked
(Werhli and Husmeier, 2007). Therefore, algorithms such as greedy hill climbing and Markov
Chain Monte Carlo (MCMC) are needed to sample from the posterior probability (Tsamardinos et
al., 2006; Hastings, 1970).
Furthermore, one constraint of the Bayesian networks is that they must be acyclic. This is
not an acceptable constraint given the prevalence of feedback loops in biology including gene
regulation (Husmeier, 2003). However, biological cause and effects such as a transcription factor
influencing the expression of a target gene does not occur simultaneously, as there is some time
delay (Husmeier, 2003). In Dynamic Bayesian networks, the way around the acyclic constraint is
to ‘unfold’ the network across time points (Husmeier, 2003). The amount of time between slices
is considered homogenous in most cases because of the increase in model complexity otherwise.
However, Zou and Conzen limited the number of potential regulators of a target to regulators that
had an earlier or simultaneous expression change to the target (Zou and Conzen, 2004).
Therefore, the transcriptional time lag can be zero to several units in this setting.
Due to the intractability of the denominator in Eq. 1.3, an appropriate heuristic approach
would be the MCMC sampling with a Metropolis-Hastings acceptance criterion to sample from
the posterior distribution (Husmeier, 2003). In the MCMC approach for dynamic Bayesian
networks edges can be added or deleted. It is worth noting that a reversal of edge direction is not
an option because in the network, which is unfolded in time, would mean that an effect preceded
a cause (Husmeier, 2003). Additionally, edges within a time slice are not allowed, as that would
mean the events happened simultaneously (Husmeier, 2003). Therefore, a new graph 𝐺𝑛𝑒𝑤 is
proposed based on the old graph 𝐺𝑜𝑙𝑑 by adding or removing an edge between time points. The
Metropolis-Hastings acceptance criterion is:
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𝑃𝑀𝐻 = min {1,

𝑃(𝐺𝑛𝑒𝑤 |𝐷) 𝑄(𝐺𝑜𝑙𝑑 |𝐺𝑛𝑒𝑤 )
×
}
𝑃(𝐺𝑜𝑙𝑑 |𝐷) 𝑄(𝐺𝑛𝑒𝑤 |𝐺𝑜𝑙𝑑 )

(1.5)

This acceptance criterion cancels out the intractable Z of the posterior probability (Eq.
1.3). Q represents the proposal probability. The Hastings ratio

𝑄(𝐺𝑜𝑙𝑑 |𝐺𝑛𝑒𝑤 )
𝑄(𝐺𝑛𝑒𝑤 |𝐺𝑜𝑙𝑑 )

is one because

without the possibility of an edge reversal move, and with the network unfolded in time, the
proposal probabilities are equal. Specifically,
𝑄(𝐺𝑜𝑙𝑑 |𝐺𝑛𝑒𝑤 )
𝑁(𝐺𝑜𝑙𝑑 )
=
𝑄(𝐺𝑛𝑒𝑤 |𝐺𝑜𝑙𝑑 )
𝑁(𝐺𝑛𝑒𝑤 )

(1.6)

Where N is the number of neighborhoods, or potential acyclic graphs created by adding
or removing an edge from the old or new graph. A potential graph would only be rejected if it’s
cyclic. Since a dynamic Bayesian network is guaranteed to be acyclic, the number of structures
that can be created by adding or removing an edge is the same for both 𝐺𝑜𝑙𝑑 and 𝐺𝑛𝑒𝑤 and the
Hastings ratio is one.
The fact that many interactions must be learned from a small number of time points
means that the prior probability would have a large impact on the overall posterior probability
(Husmeier, 2003). Several studies have devised priors from various types of biological data
(Imoto et al., 2003; Werhli and Husmeier, 2007; Zheng et al., 2011; Chen et al., 2013; Baur and
Bozdag, 2015).
One common type of prior for incorporating multiple types of biological data was
adapted in several studies (Imoto et al., 2003; Werhli and Husmeier, 2007; Zheng et al., 2011;
Chen et al., 2013; Baur and Bozdag, 2015). The prior takes the form of a Gibbs distribution (Eq.
1.7) where prior information was encoded by an energy function (Eq. 1.8), and 𝑍(𝛽) was a
normalizing constant. The hyperparameter, 𝛽, measured the influence of the prior information
relative to the time series expression data (Werhli and Husmeier, 2007). Using one source of prior
knowledge could easily be extended to incorporating multiple sources of prior knowledge
simultaneously as described in Werhli and Husmeier, 2007.
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𝑃(𝑆|𝛽) =

𝑒 −𝛽𝐸(𝑆)
𝑍(𝛽)

(1.7)

The energy function measured how closely the prior information matched with the
network structure at the current step of MCMC (Eq. 1.8). In energy function, B is the prior
matrix, and G is the current network structure (Werhli and Husmeier, 2007). As the energy goes
to zero, there is more agreement between the prior and the network structure.
𝑁

𝐸(𝑆) = ∑ |𝐵𝑖𝑗 − 𝐺𝑖𝑗 |

(1.8)

𝑖,𝑗=1

Imoto et al. used this prior to integrate binding site information, protein-protein
interactions and protein-DNA interactions (Imoto et al., 2003). Werhli and Husmeier used it to
include binding site information (Werhli and Husmeier, 2007). In a couple of studies, the prior
was used to include histone modification data (Chen et al., 2011; Zheng et al., 2013). The idea
behind these two studies is that genes with correlated histone modification profiles are more
likely to interact. Therefore, the histone modification data can be used as prior information to
integrate along with the time series gene expression data.

1.3.4. Infer cancer-related miRNA-gene module drivers

A few studies have developed computational methods to establish miRNA-gene modules
(Karim et al., 2016; Jin and Lee, 2015; Zhao et al., 2015). Karim et al. outlined a methodology to
infer miRNA-gene modules through collective group relationships (2016). From the correlation
matrix of miRNA expression and gene expression, a matrix of collaboration scores was computed
for miRNAs, which reflected the similarity or collaboration in regulating the same target genes.
Another matrix of collaboration scores was also computed for genes, which reflected their
similarity in being regulated by the same miRNAs. Both matrices underwent clustering
separately. Groups of miRNAs that regulate the same genes were formed, and groups of genes
regulated by the same miRNAs were formed by clustering the collaboration scores. Canonical
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correlation analysis was used to establish relationships between the groups of miRNAs and the
groups of genes, retaining the relationships that had the highest canonical correlation.
Jin and Lee used a Bayesian approach to identify miRNA-gene modules in cancer (Jin
and Lee, 2015). First, a biclustering approach was used on the gene expression data to form genesample modules. Gene-sample modules were used since cancer is a heterogeneous disease even
between patients with the same type of cancer. These gene-sample subsets are likely to be
functionally related. A Bayesian network approach was used to connect candidate miRNAs to the
genes in the gene-sample module. A network was constructed based on the likelihood of a set of
genes and a set of miRNAs as a joint distribution.

1.4 Organization of the Dissertation

Each chapter following the introduction is based on a manuscript that is either published,
submitted or in preparation for publication. Some introductory content from each manuscript was
moved to this chapter to motivate the work and allow for clarity and elaboration on the current
literature. Additionally, some supplemental materials published or submitted along the papers
were added to their respective chapters for continuity. The final chapter summarizes the main
conclusions of the dissertation and presents future work for integrating multiple types of
biological data to infer interactions. Each chapter addresses each aim in the order that they appear
in this introduction.
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CHAPTER 2

A feature selection algorithm to compute gene centric methylation from probe level
methylation data

This chapter appears in Baur and Bozdag, PLoS ONE, 2016

Abstract: DNA methylation is an important epigenetic event that affects gene expression during
development and various diseases such as cancer. Understanding the mechanism of action of
DNA methylation is important for downstream analysis. In the Illumina Infinium
HumanMethylation 450K array, there are tens of probes associated with each gene. Given
methylation intensities of all these probes, it is necessary to compute which of these probes are
most representative of the gene centric methylation level. In this study, we developed a feature
selection algorithm based on sequential forward selection that utilized different classification
methods to compute gene centric DNA methylation using probe level DNA methylation data. We
compared our algorithm to other feature selection algorithms such as support vector machines
with recursive feature elimination, genetic algorithms and ReliefF. We evaluated all methods
based on the predictive power of selected probes on their mRNA expression levels and found that
a K-Nearest Neighbors classification using the sequential forward selection algorithm performed
better than other algorithms based on all metrics. We also observed that transcriptional activities
of certain genes were more sensitive to DNA methylation changes than transcriptional activities
of other genes. Our algorithm was able to predict the expression of those genes with high
accuracy using only DNA methylation data. Our results also showed that those DNA
methylation-sensitive genes were enriched in Gene Ontology terms related to the regulation of
various biological processes.
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2.1 Introduction

Methylation of cytosine nucleotides in DNA (hereafter DNA methylation) is involved in
cellular differentiation (Meissner et al., 2008), development (Bird, 2002) and has impact in
diseases such as cancer (Jones and Baylin, 2007). DNA methylation is typically associated with a
decrease in gene expression due to its role in blocking transcription factors from binding (Jones,
2012). It is also speculated that silencing of a gene could precede DNA methylation (Jones,
2012). DNA methylation is also known to have positive correlation with gene expression, as well,
particularly in gene bodies (Jones, 2012). Several studies integrate DNA methylation with gene
expression to unravel the role of DNA methylation in gene regulation (Brenet et al., 2011; Varley
et al, 2013; Rhee et al., 2013; Baur and Bozdag, 2015).
In the Illimina Infinium 450K DNA methylation array, each gene is associated with
around 18 DNA methylation probes. In this study, we developed a feature selection algorithm
based on sequential forward selection that can utilize various classification methods to select
probes that are relevant to gene expression from the 450K array. We also tested this algorithm
against more sophisticated approaches such as support vector machines with recursive feature
elimination (SVM-RFE), a genetic algorithm and ReliefF. Additionally, we compared our
algorithm against several selection methods that do not use gene expression to inform the
selection. These methods include choosing the probe with the greatest variation, choosing probes
close to the TSS, and choosing probes in upstream CpG islands. Following the selection of
probes, we computed several metrics to evaluate the prediction quality of gene expression by the
selected probes. These metrics included precision, recall, specificity and Matthew’s correlation
coefficient. Our results showed that our sequential forward selection algorithm performed best on
all metrics when using K-Nearest Neighbors (KNN) where K = 1 (1NN). Our algorithm generally
selects one or two probes for each gene, which allows to us identify key regions where DNA
methylation changes have impact on gene expression.
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We also observed that our algorithm could determine genes whose expression levels are
putatively sensitive to the changes in their DNA methylation. We showed that these DNA
methylation-sensitive genes were enriched for Gene Ontology (GO) terms related to the
regulation of various biological processes. Additional functional analysis clustering showed that
DNA methylation-sensitive genes also regulated other genes and proteins by a variety of
mechanisms, including DNA-binding, kinase activity, protein degradation and protein synthesis.

2.2. Materials and Methods

2.2.1 Data

Agilent whole genome microarray data and Illumina 450K DNA methylation data of 25
breast cancer lines after treated with the hypomethylating agent, 5-azacitidine (aza) for 72 hours
were downloaded from (Li et al., 2014) (GSE57343). Log10 Mock/Aza expression data were
normalized to account for the different cell lines using LoEss normalization in the LIMMA
package (Schuebel et al., 2007; Smith, 2005). To perform binary prediction of gene expression,
the expression data were discretized into up, down and baseline categories using 1.1-fold change
threshold for aza-treated cells with respect to mock trials (mock/aza). Baseline mock/aza values
were removed. The up and down-expressed mock/aza samples were the binary classifiers in the
classification algorithms.
To verify the results of our algorithm on breast cancer cell line, we also downloaded
Illumina 450K DNA methylation and Agilent mRNA expression data for 99 Luminal A breast
cancer samples from the TCGA repository (The Cancer Genome Atlas Network, 2012). Batch
effects were corrected in the mRNA expression data using the LIMMA package (Smith, 2008).
Expression data were discretized with a log2 1.2-fold change of the expression level of the
sample over the median expression level for that gene across samples. We used the 1.2-fold
change threshold instead of 1.1 in tissue samples to reduce potential noise in the discretized data.
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Baseline sample expression/median expression values were removed. The up and downexpressed sample expression/median expression were the binary classifiers in the classification
algorithm.

2.2.2. A sequential feature selection algorithm for classification methods

We developed a sequential feature selection (SFS) algorithm that can use different
classification methods to select the probes that are most relevant to gene expression (Algorithm
1). SFS sequentially adds features until there is no improvement in the prediction. The objective
function of the SFS algorithm is the minimization of the mean classification error in a 10-fold
cross-validation (CV).
Algorithm 1 describes the process for a single gene and a set of n probes associated with
the gene, X. Given the DNA methylation levels of the probes, 𝑀𝑘,𝑋 , and the associated gene
expression levels, 𝑦𝑘 , each probe is individually tested in a 10-fold cross validation predicting
the gene expression based on the DNA methylation levels of the probe (steps 1-5). In each
partition of the 10-fold cross validation, the specified classification algorithm (described below)
is trained on the training samples. The expression levels of test samples are predicted based on
the trained classification algorithm and the methylation levels of the test samples. The number of
test samples in which the predicted expression level does not match the true expression level is O.
O is computed for every partition and the mean(O) is the classification error, CCE. The probe
with the best performance, or minimal CCE, in the 10-fold cross validation is selected (steps 6-8).
Additional probes are sequentially added from the pool of remaining probes if the
performance in a 10-fold cross validation improves and more samples are predicted correctly
(steps 9-18). If no additional probes lead to increased performance, the algorithm is terminated
(steps 19-21).
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Algorithm 1. Sequential feature selection with 10-fold CV
Input: 𝑦𝑘 : discretized up/down gene expression of sample size k
X=(𝑥1 , 𝑥2, … . 𝑥𝑛 ): n potential probes associated with gene to be added to S
𝑀𝑘,𝑋 : DNA methylation values for n probes associated with gene in k samples
S: current set of selected probes, initially empty
C: Classification model based on training folds in 10-fold CV
C = Classification (𝑀𝑡𝑟𝑎𝑖𝑛,𝑆 , 𝑦𝑡𝑟𝑎𝑖𝑛 ),
𝑂( 𝑀𝑡𝑒𝑠𝑡,𝑆 , 𝑦𝑡𝑒𝑠𝑡 ) = 𝑠𝑢𝑚(𝑦𝑡𝑒𝑠𝑡 ≅ predict(C, 𝑀𝑡𝑒𝑠𝑡,𝑆 ))
Current classification error (CCE): A vector of classification errors for probes being tested, the
classification error is mean(O) from a 10-fold CV
1. For i=1:n
2.
Select probe 𝑥𝑖
3.
Compute 10-fold CV. In each partition, compute C on training and O on test data
4.
Take mean O as current classification error, CCE(i)
5. End
6. Find j s.t. CCE(j) < CCE(i), 1 ≤ i ≤ n, i ≠ j
7. Move probe 𝑥𝑗 from X to S
8. Old classification error, OCE = CCE(j)
9. While (true)
10.
For each 𝑥𝑖 ∈ 𝑋
11.
Select probes {𝑥𝑖 } ∪ 𝑆
12.
Compute 10-fold CV. In each partition, compute C on training and O on test
data.
13.
Take mean O as current classification error, CCE(i)
14.
End For
15.
Find j s.t. CCE(j) < CCE(i), 1 ≤ i ≤ |X| , i ≠ j
16.
If CCE(j) < OCE17.
Move probe 𝑥𝑗 from X to S
18.
OCE = CCE(j)
19.
Else:
20.
Stop search
21. End While

We used the following classification algorithms in combination with sequential feature selection
(Algorithm 1).
Support vector machine (SVM): A linear kernel function was used to map the training data to
the kernel space (Cortes and Vapnik, 1995). Sequential minimal optimization was used to find the
separating hyperplane.
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K-Nearest neighbors (KNN): KNN classification algorithm was applied with K = 1,3 and 5
(1NN, 3NN and 5NN, respectively). A Euclidean distance metric was used for all instances of
KNN (Friedman et al., 1977).
Decision trees (DT): The minimum parent size (number of observations) was 10 and the
minimum leaf size was 1 (Quinlan, 1999).
Naïve Bayes (Bayes): A kernel distribution was specified for predictors in the Naïve Bayes
classification algorithm (John et al., 1995).
We also tested other feature selection algorithms, SVM with recursive feature elimination (SVMRFE), a genetic algorithm feature selection with KNN classification (GA-KNN) and ReliefF.
SVM-RFE: The SVM-RFE algorithm was adapted from (Yan and Zhang, 2015). This study used
a correlation bias reduction strategy to deal with highly correlated features. In our adaptation, we
also included a modification to deal with class imbalances, such that the weight of misclassifying
the minority class was higher. The weights of the penalties were obtained by solving the equation
n0*w0=n1*w1, where n0 and n1 were the number of down and up expressed samples, and w0
and w1 were the respective weights. We used a Gaussian kernel and ranked the features. For each
gene, we selected the top k probes where k equals to the number of probes selected in the SFS
algorithm.
GA-KNN: A genetic algorithm for selecting features was adapted from (Babatunde et al., 2014).
The goal of the GA algorithm was to minimize the fitness function:

𝑟𝑒𝑠𝑢𝑏𝐿𝑜𝑠𝑠
,
𝑁−𝑆

where resubLoss is

the resubstitution loss in a KNN classification (fraction of misclassified data), N is the total
number of features and S is the number of selected features. The denominator of the equation
penalizes a large number of selected probes. We tested the algorithm using K=1, 3 and 5.
ReliefF: A KNN-based ReliefF implementation from the MATLAB statistics toolbox was also
tested. The nearest “hit” of a feature vector for a sample was defined as the closest sample of the
same class by Euclidean distance. The nearest “miss” of a feature vector for a sample was defined
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as the closest sample of the other class. For each iteration, a vector of features from a random
instance is selected. The weight of the feature i is updated according to the function:
𝑊𝑖 = 𝑊𝑖 − (𝑥𝑖 − ℎ𝑖 )2 + (𝑥𝑖 − 𝑚𝑖 )2
where 𝑥𝑖 is the value of the feature of the randomly selected instance, ℎ𝑖 is the nearest hit and 𝑚𝑖
is the nearest miss. Therefore, the weight of a feature decreases if it is more distant from nearby
instances of the hits relative to the misses.
We tested this algorithm with K = 1, 3 and 5. This implementation ranks the predictors in order
of importance. For each gene, we selected the top k probes where k equals to the number of
probes selected in the SFS algorithm.
We also developed two control algorithms namely random and top two correlated.
Random: For a given gene, we randomly selected probes associated with the gene. We set the
number of probes randomly selected for a gene equal to the number of probes that were selected
in the SFS algorithm that we compared to.
Top two correlated: The two probes most positively or negatively correlated with gene
expression were selected.
We tested our algorithm against following probe selection methods, which do not consider gene
expression.
All: For a given gene, all the probes associated with the gene are selected.
Upstream CpG Island: For a given gene, we selected probes that are in CpG islands in the
upstream regions (TSS200, TSS1500, 5’ UTR and 1st Exon).
TSS: For a given gene, we selected probes within a 2500bp window of the transcription start site.
Top SD: For a given gene, the probe with the highest standard deviation is selected.

2.2.3. Assessment of algorithms
We calculated various metrics to test each algorithm’s ability to predict gene expression
based on the selected DNA methylation probes. We applied a leave-one-out cross validation
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(LOO-CV) with an appropriate model using the selected probes as predictors and the discretized
gene expression as a response. For the SFS algorithm, the classification model used in the feature
selection was used in the LOO-CV. For GA-KNN and ReliefF, KNN was used in the LOO-CV.
For SVM-RFE, SVM was used in the LOO-CV. For the methods that do not integrate gene
expression, namely All, Upstream CpG Island, TSS and Top SD, we evaluated the probe
selection with a LOO-CV using KNN, DT, SVM and NB.
Following the LOO-CV, we computed the number of true positive (TP), true negatives
(TN), false positives (FP) and false negatives (FN) and calculated various metrics. We considered
down-expressed cases positive and up-expressed cases negative outcomes. We calculated the
prediction accuracy ((TP + TN)/(TP+TN+FP+FN)), recall (TP/(TP+FN)), precision
(TP/(TP+FP)) and specificity (TN/(TN+FP)) for each method. We also computed Matthew’s
correlation coefficient (MCC) [Eq 2.1]. MCC can be considered a balanced measure of accuracy
even when the class sizes may be different.

𝑇𝑃×𝑇𝑁 − 𝐹𝑃 × 𝐹𝑁
√(𝑇𝑃 + 𝐹𝑃)(𝑇𝑃 + 𝐹𝑁)(𝑇𝑁 + 𝐹𝑃)(𝑇𝑁 + 𝐹𝑁)

(2.1)

2.2.4. Gene Ontology and functional enrichment

To perform functional analysis on genes whose expression were predicted with high
accuracy by DNA methylation, we selected genes that have an MCC > 0.6 in the SFS algorithm.
We performed a GO-term enrichment analysis using the web tool GOrilla (Eden et al., 2009), by
comparing the list of genes with high MCC to a background of the full list of 17,043 genes in the
dataset. To show that the enrichment of GO terms obtained is specific to genes with high MCC,
we compared the list of GO terms and p-values for genes with high MCC to the list of GO terms
and p-values for genes with MCC < 0.2.
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To investigate if there are any functional differences between genes that have gene body
and upstream methylation, we performed gene functional classification clustering using DAVID
(Huang et al., 2008). Given an input gene list, the DAVID’s functional clustering tool generates a
gene-to-gene similarity matrix based on shared functional annotations from different sources
(Huang et al., 2007). A clustering algorithm classifies the genes into functionally related clusters.
Each functional cluster contains certain related terms shared between the genes in the group. We
separated all genes with MCC > 0.6 based on whether the selected probes by the SFS algorithm
were exclusively from upstream regions (gene had probes only in 5’ UTR, 1st Exon, TSS200 or
TSS1500 as defined by Illumina) or exclusively from the gene body applied functional clustering
using DAVID for each group of genes.

2.2.5. Implementation

Our algorithm is unbiased as it does not restrict analysis by CpG status or genomic
position. We implemented the tool in MATLAB. The source code is freely available under the
MIT Open Source license (https://github.com/brittanybaur/genecentricmethylation)

2.3. Results and Discussion

2.3.1. KNN-SFS algorithm resulted in higher recall and specificity

We calculated the prediction accuracy, specificity, recall, precision and Matthews
Correlation Coefficient (MCC) for the SFS algorithm using the four different classification
algorithms on 31,171 transcripts on the breast cancer cell line data obtained from Li et al., 2014.
We calculated various metrics such as precision, recall, specificity and MCC due to the class
imbalance of up/down expressed samples. We found that the 1NN-SFS algorithm resulted in the
highest MCC, recall and specificity, and the third highest precision (Table 2.1, Fig. 2.1).
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Table 2.1. Mean performance of SFS algorithms and controls on the breast cancer cell line
data.
1NN
3NN
5NN
Bayes
DT
SVM 1NN
1NN
Random Top
Two
Accuracy
0.79
0.80
0.74
0.78
0.77
0.74
0.66
0.67
Precision

0.70

0.74

0.65

0.75

0.68

0.64

0.53

0.54

Recall

0.68

0.65

0.53

0.59

0.65

0.63

0.53

0.53

Specificity

0.70

0.67

0.56

0.62

0.66

0.63

0.55

0.55

MCC

0.40

0.40

0.16

0.35

0.33

0.26

0.08

0.08

Figure 2.1. Violin plots of performance metrics for the algorithm when utilizing different
classification methods in the SFS algorithm and controls on the breast cancer cell line data.
A) MCC, B) Precision, C) Recall, D) Specificity. Green squares specify the median and the red
pluses specify the mean. Bayes: Naive Bayes, DT: Decision tree, SVM: Support Vector Machine.
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The 1NN algorithm also resulted in the second highest accuracy (Fig. 2.2A). We
compared the 1NN-SFS algorithm to the random and top two correlated selection methods and
evaluated the predictive performance of the probe selection with a 1NN-based LOO-CV. To
ensure a fair comparison, we set the number of probes selected for a gene in the 1NN-Random
method equal to the number of probes selected for that gene in the 1NN-SFS algorithm. We
found that all these controls resulted in worse performance than our algorithm (Fig. 2.1., Fig.
2.2A).

Figure 2.2. Violin plots of accuracy. A) SFS algorithms using various classification algorithms,
B) GA and ReliefF algorithms.

We also compared 1NN-SFS algorithm to GA-KNN and ReliefF algorithms for K=1, 3
and 5, and to the SVM-RFE algorithm. We set the number of top ranked probes selected in
ReliefF and SVM-RFE equal to the number of probes selected by 1NN-SFS. We observed that
the 1NN-SFS algorithm performed better than GA-KNN and ReliefF algorithms for K=1, 3 and5,
and the SVM-RFE algorithm by all metrics (Fig. 2.3, Fig 2.2B). Taken together, these results
indicate that the 1NN-SFS feature selection method chooses more relevant probes than other
algorithms.
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Figure. 2.3. Violin plots of performance metrics for 1NN-SFS algorithm against other
algorithms on the breast cancer cell line data. A) MCC, B) Precision, C) Recall, D)
Specificity. Random: KNN random, Top 2: KNN top two (see Methods). GAK: GA-KNN
algorithm with varying K-nearest neighbors. RFK: Relief-F algorithm with varying K nearest
neighbors.

We compared the 1NN-SFS algorithm to probe selection methods that do not consider
gene expression. These approaches to probe selection resulted in significantly lower performance
when compared to the 1NN-SFS algorithm that integrate gene expression, suggesting the
importance of integrating gene expression data to inform the probe selection (Fig. 2.4).
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Figure 2.4. Violin plots of MCC for 1NN-SFS algorithm against other probe selection
methods on the breast cancer cell line data. A) All, B) Upstream CpG Island, C) TSS, D) Top
SD.

We observed the 1NN algorithm usually only selected one or two probes per gene (Fig.
2.5). Out of the 31,171 transcripts tested, 11,833 transcripts had one probe selected and an
additional 9,411 transcripts had two probes selected. Since selecting all the probes (no feature
selection) leads to significantly poorer performance, the selection of the best one or two probes is
important to the algorithm’s good performance. This shows that our algorithm was able to reduce
the number of probes for a given gene to a limited number of key informative probes.
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Figure 2.5. Number of probes selected per gene by 1NN-SFS algorithm on the breast cancer
cell line data.

2.3.2. KNN algorithm resulted in consistent prediction accuracy

To check the consistency of the algorithm on smaller subsets of the data, we ran the
algorithm five additional times on half of the dataset, in which the samples were randomly chosen
each execution. For each of the five executions, we compared 1NN-SFS algorithm to random
selection method and top two correlated method. Fig. 2.6 shows a heatmap comparison of the
MCC for the five runs of the 1NN algorithm compared to the random selection and top two
correlated selection. The 1NN consistently gave higher MCC values over the random selection
and top two correlated selection. Additionally, the MCC values were consistent across runs.
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Figure 2.6. Heatmap clustering of MCC values. Heatmap clustering of MCC values for five
executions of the algorithm on random halves of the breast cancer cell line data for A) 1NN
algorithm and B) random selection of probes C) Top two correlated approach.

2.3.3. DNA methylation-sensitive genes were enriched for regulation-based GO terms

We investigated if there are any common functional property on genes whose
transcription levels are sensitive to DNA methylation changes by analyzing genes where the
selected probes predict gene expression well. 3,084 genes had MCC > 0.6 in the 1NN-SFS
algorithm. The GOrilla results are summarized in Table 2.2, showing that DNA methylationsensitive genes were enriched for GO terms related to the regulation of various biological
processes. The table encompasses only the top 30 significant GO terms.
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Table 2.2. Top 30 GO Terms for genes with MCC >0.6 by 1NN-SFS algorithm on the breast
cancer cell line data.
Description
FDR q-value
regulation of multicellular organismal process
4.43E-19
regulation of developmental process
2.51E-17
regulation of multicellular organismal development
9.31E-17
positive regulation of biological process
1.16E-16
movement of cell or subcellular component
1.23E-16
positive regulation of cellular process
1.41E-16
negative regulation of biological process
2.3E-16
anatomical structure development
1.38E-15
negative regulation of cellular process
2.72E-15
regulation of cell differentiation
2.85E-15
cell migration
6.81E-15
negative regulation of metabolic process
2.48E-14
anatomical structure morphogenesis
3.53E-14
organ development
5.3E-14
transmembrane receptor protein tyrosine kinase signaling pathway
6.02E-14
cell motility
7.21E-14
Locomotion
1.7E-13
developmental process
1.71E-13
enzyme linked receptor protein signaling pathway
1.75E-13
single-organism developmental process
1.76E-13
regulation of cell development
2.88E-13
regulation of anatomical structure morphogenesis
4.5E-13
negative regulation of macromolecule metabolic process
6.04E-13
intracellular signal transduction
8.58E-13
single-multicellular organism process
2.36E-12
multicellular organismal process
5.86E-12
regulation of localization
1.06E-11
positive regulation of multicellular organismal process
1.07E-11
signal transduction
1.27E-11
cellular component organization or biogenesis
1.39E-11
positive regulation of developmental process
3.2E-11

To verify that this result is specific to well-predicted genes, we compared the result to
poorly-predicted genes. We performed GO analysis on 2,880 genes that have MCC < 0.2. We
chose MCC thresholds carefully to ensure a fair comparison to GO analysis by having
comparable gene set sizes. Table 2.3 shows that only immune response and stimulus detection
terms are reported as significant. This result suggests that enrichment of regulation-related GO
terms is specific to genes with high MCC values.
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Table 2.3. GO terms with MCC < 0.2 for genes by 1NN-SFS algorithm on the breast cancer
cell line data.
Description
FDR q-value
detection of chemical stimulus involved in sensory perception of smell
5.62E-11
detection of chemical stimulus involved in sensory perception
5.74E-11
detection of chemical stimulus
5.62E-8
detection of stimulus involved in sensory perception
1.07E-7
detection of stimulus
1.95E-3
immune response
1.23E-2

We applied DAVID’s functional classification tool on genes with MCC > 0.6 to
determine functional enrichment differences for genes with selected gene body probes and genes
with selected promoter probes. 1035 genes had exclusively upstream probes selected, resulting in
33 functional clusters. 699 genes had exclusively gene body probes selected, resulting in 27
functional clusters. We found that in both the promoter and gene body group, many of the clusters
suggested that the genes are involved in the regulation of other genes and proteins via a variety of
mechanisms. The most enriched clusters are shown in Tables 2.4 and 2.5.

Table 2.4. Functional clusters of genes with MCC > 0.6 with upstream probes selected by
1NN-SFS algorithm on the breast cancer cell line data.
Cluste
r Num
1

Size
40

Enrich
ment
4.39

2

4

3.67

3

45

3.46

4

13

3.42

5

5

3.18

6

6

3.05

Most significant terms (p-val)
Atp-binding (4.4E-45), Nucleotidebinding (4.6E-38), adenyl
ribonucleotide binding (1.7E-37)
Repeat:ANK 1 (1.7E-6),
Repeat:ANK 2 (1.8E-6), Ankyrin
(2.9E-6)
Kinase (1.8E-56), Protein Kinase –
ATP binding site (2.0E-56),
domain: protein kinase (2.1E-53)
Microtubule cytoskeleton (9.6E-15),
cytoskeleton (9.1E-14), cytoskeletal
part (4.1E-12)
Nucleolus (8.8E-6), nuclear lumen
(1.6E-4), intracellular organelle
lumen (3.7E-4)
Regulation of actin filament
polymerization (8.4E-13),
regulation of actin filament
polymerization or depolymerization
(1.6E-12), regulation of actin
filament length (1.9E-12)

Other representative terms (pval) and notes
Helicase (4E-12), kinase (5.8E-6),
protein kinase activity (3.7E-4)
Genes coding for ankyrin proteins

Phosphorylation (1.7E-51),
transferase (1.1E-47), nucleotide
binding (2.1E-34)
Centrosome (2.3E-8), genes
involved in regulation of cell
motility
Membrane enclosed lumen (4.4E4)
Regulation of protein complex
assembly (1.2E-11), negative
regulation of actin filament
depolymerization (6.3E-11)
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7

4

2.91

8

5

2.83

9

6

2.66

10

16

2.54

11

13

2.48

12

8

2.38

13

59

2.29

14

8

2.26

15

5

2.23

16

4

1.85

17

5

1.84

18

7

1.73

19

10

1.72

20

14

1.62

binding site:S-adenosyl-Lmethionine (1.8E-8), s-adenosyl-lmethionine (1.5E-7),
methyltransferase (4.3E-7)
Microfilament motor activity
(22.0E-12), actin filament-based
movement (6.3E-12),
domain:Myosin head-like (9.4E-12)
Anti-apoptosis (7.8E-12), negative
reglation of apoptosis (1.2E-8),
negative regulation of programmed
cell death (1.3E-8)
Nucleotide phosphate-binding
region:GTP (4.7E-28), gtp-binding
(2.3E-27), Ras (2.7E-16)
Mitosis (2.5-22), nuclear division
(2.5E-22), M phase of mitotic cell
cycle (3.2E-22)
Guanine-nucleotide dissociation
stimulator, CDC4, conserved site
(1E-14), guanyl-nucleotide
exchange factor activity (1.6E-14),
Dbl homology (DH) domain (2.8)
Transcription regulator activity
(2.7E-50), transcription regulation
(2.2E-47), regulation of
transcription, DNA dependent
(2.2E-47)
LIM domain (6.9E-18), Zinc finger,
LIM-type (2.3E-17), zinc (2.5E-7)
ABC transporter-like (9E-8), ABC
transporter, conserved site (1.5E-7),
ATPase activity (4.2E-7)
Negative regulation of translation
(1.5E-8), translation regulation
(4.0E-8), mRNA 5’-UTR binding
(2.7E-7)
Protein tyrosine phosphatase
activity (3.9E-9), tyrosine-specific
phosphatase (1.5E-8),
dephosphorylation (1.6E-8)
Purine ribonucleoside triphosphate
biosynthetic process (1.1E-10),
purine nucleoside triphosphate
biosynthetic process (1.1E-10)
ribonucleotide triphosphate
biosynthetic process (1.1E-10),
Ribosomal protein (6.7E-19),
structural constituent of ribosome
(8.2E-18), cytostolic ribosome
(1.6E-17)
Wd repeat (8.2E-25), WD40 repeat
(3.3E-24), WD40 repeat, conserved
site

Genes coding for
methyltransferases

Genes coding for myosin proteins

Genes predominately related to
BCL2 (BAG3, BAG4, BCL2A1,
BL210). Also includes MCL1 and
TNFRSF10D
Genes predominately related to the
RAS oncogene family
Organelle fission (4.1E-22), cell
division (1.3E-17)
Regulation of Ras protein signal
transduction (2.0E-13), regulation
of small GTPase mediated signal
transfuction (7.2E-13), regulation
of Rho protein signal transduction
(9.2E-12)
Sequence specific DNA-binding
(3.1E-29), repressor (6.0E-22)

Metal-binding (2.1E-6)
Members of ATP-binding cassette
sub-family (ABC)
Insulin-like growth factor 2 (IGF2)
mRNA binding proteins

Phosphatases

Various ATPase coding genes

Genes coding for ribosomal
proteins

Genes with WD domain.
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Table 2.5. Functional clusters of genes with MCC > 0.6 with gene body probes selected by
1NN-SFS algorithm on the breast cancer cell line data.
Cluster
Num

Number
of genes

Enrichment

Most significant terms (p-val)

Other representative
terms (p-val) and notes

1

48

2.84

phosphorylation (4.8E-33),
kinase (7.6E-40),
transferase(1.9E-29)

2

12

2.36

Atp-binding (1.1E-51),
Nucleotide-binding (6.5E-47),
adenyl ribonucleotide binding
(4.2E-45)
Nucleolus (1.2E-14), nuclear
lumen (3.9E-11), intracellular
organelle lumen (3.7E-10)

3

11

2.06

4

9

1.83

5

8

1.64

Cytoskeleton (1.7E-7),
microtubule cytoskeleton (2.8E6), intracellular non-membranebounded organelle (1.4E-5)

6

9

1.62

GTP-binding (6.7E-15), guanyl
nucleotide binding (5.2E-13),
small GTPase mediated signal
transduction (2.8E-12)

Ras oncogene related genes
(RHOF, RAB3B, RAB3D,
NKIRAS2, ERAS)

7

7

1.47

RNA-recognition motif, RNP-1
(3,8E-12), nucleotide-binding,
alpha-beta plait (4.1E-12), RNA
binding (4.8E-10)

RNA binding proteins and
ribonucleoproteins

8

6

1.39

Negative regulation of ubiquitinprotein ligase activity during
mitotic cell cycles (2.2E-12),
negative regulation of ubiquitinligaase activity (2.6E-12)

Genes coding for
proteasomes and ubiquitin

9

66

1.38

10

6

1.28

Regulation of transcription
(1.1E-34), transcription (2.4E24), transcription regulation
(5.0E-32)
Homeobox (30E-10), Homebox,
conserved site (5.0E-10),
homeodomain-related (5.7E-10)

11

7

1.28

12

4

1.17

Transcription regulation (1.6E10), transcription(2.1E-10),
regulation of transcription (6.8E8)
Ribosomal protein (7.2E-17),
ribonucleoprotein (1.8E-15),
ribosome (5.6E-15)

Tpr-repeat (3.0E-13),
tetratricopeptide-like helical
(6.4E-13), tetratricopeptide
region (3.9E-8)
SNF2-reated (6.4E-9),
domain:Helicase C-terminal
(1.6E-7), domain:Helicase ATPbinding (1.9E-7)

RNA binding (2.8E-4)

Homeobox proteins

Chromodomain helicase
DNA binding protein
family
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13

4

1.09

Protein import into nucleus,
docking (1.6E-19), nuclear pore
(2.3E-7_ nuclear import (2.7E-7)

Exportin 1, nucleoporin,
transportin 2, importin 5

For genes with probes selected from the promoter regions (Table 2.4), the most enriched
cluster contains genes involved in ATP-binding, nucleotide-binding, helicase and protein kinase
activity. Additionally, cluster 3 also contains many kinase, phosphorylation and nucleotide
binding terms. A common theme is that these terms are all mechanisms by which other genes and
proteins can be regulated. Importantly, these functions may be related to the regulation-based GO
terms represented in the GOrilla analysis. Other possible mechanisms of regulation of other genes
and proteins include an enrichment of DNA-methyltransferases (cluster 7) and regulation of
protein synthesis via ribosomal protein (cluster 19). DNA methylation may also play a role in the
regulation of apoptosis-related genes (cluster 9) and cell motility (cluster 8). A group of 59 genes
were enriched in terms related to transcription regulator activity (cluster 13).
Similar results were obtained for genes where the probes were selected from gene body
regions (Table 2.5). The first and third cluster involve transcription regulation and protein kinase
activity. Cluster 4 contains additional genes coding for ribosomal proteins. Cluster 8 contains
genes coding for proteasomes and ubiquitin, suggesting that protein degradation may also be
under the control of DNA methylation of certain genes. Additionally, 66 genes were enriched in
terms related to transcription regulation (cluster 9).
Together, these results suggest that if DNA methylation is a good predictor of gene
expression (MCC > 0.6) than that gene may likely be involved in the regulation of other genes
and proteins through a variety of mechanisms including DNA binding, protein kinase activity,
protein synthesis and protein degradation. We did not find a significant functional difference
between genes where gene body probes are selected and genes where upstream probes are
selected. This suggests that a gene under strong epigenetic control via DNA methylation is more
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likely to be a regulatory gene, regardless of the genomic position of the predictive DNA
methylation.

2.3.4. Verification in TCGA luminal A breast cancer data

To verify our work in another dataset, we performed the 1NN-SFS algorithm on 99
luminal A breast cancer samples from the TCGA database. We computed the performance
metrics, and found the average to be 0.7 for all metrics (Fig. 2.7).

Figure 2.7. Performance metrics of 1NN-SFS algorithm on TCGA data.

We performed the same GO-term analysis for luminal A data that we performed in the
cell line data. We chose 1,823 and 1,407 genes that were predicted with an MCC > 0.6 and MCC
< 0.2, respectively. 534 of the genes with MCC > 0.6 in the TCGA data overlapped with the
genes with MCC > 0.6 in the cell line data (hypergeometric p-value < 2.01 e-41). Table 6 shows
only the top 30 GO terms for genes with high MCC and Table 7 shows all of the GO terms for
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genes with low MCC. Similar to our previous result for the cell line data, we found that genes that
predicted well were again enriched in GO-terms related to the regulation of various biological
processes while genes that were predicted poorly were not. We note here that the poorlypredicted genes had GO-terms involved in the detection of a chemical stimulus and smell. This
was due to a single family (olfactory receptor family) where almost all of the members of the
family had their expression predicted poorly. This was not the case for the regulation-based terms
in the well-predicting gene set.
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Table 2.6. Top 30 GO terms with MCC > 0.6 for genes by 1NN-SFS algorithm on TCGA
data.
Description
FDR q-value
positive regulation of cellular process
3.75E-8
positive regulation of biological process
2E-7
RNA metabolic process
3.6E-7
regulation of metabolic process
7.55E-7
regulation of transcription from RNA polymerase II promoter
8.6E-7
cellular macromolecule metabolic process
9.69E-7
regulation of gene expression
1.16E-6
regulation of macromolecule metabolic process
1.19E-6
regulation of macromolecule biosynthetic process
1.35E-6
regulation of cellular macromolecule biosynthetic process
1.36E-6
RNA biosynthetic process
1.45E-6
regulation of primary metabolic process
1.54E-6
regulation of biosynthetic process
1.56E-6
macromolecule metabolic process
2.36E-6
aromatic compound biosynthetic process
2.48E-6
regulation of cellular biosynthetic process
2.52E-6
positive regulation of RNA biosynthetic process
3.02E-6
regulation of RNA biosynthetic process
3.12E-6
nucleobase-containing compound biosynthetic process
3.4E-6
nucleic acid metabolic process
3.44E-6
regulation of cellular metabolic process
3.45E-6
regulation of transcription, DNA-templated
3.63E-6
cellular process
3.73E-6
heterocycle biosynthetic process
3.93E-6
cellular nitrogen compound biosynthetic process
4.29E-6
positive regulation of macromolecule biosynthetic process
4.35E-6
regulation of nucleic acid-templated transcription
5.11E-6
nucleobase-containing compound metabolic process
6.76E-6
regulation of nucleobase-containing compound metabolic process
1.04E-5
positive regulation of RNA metabolic process
1.07E-5
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Table 2.7. GO terms with MCC < 0.2 for genes by 1NN-SFS algorithm on TCGA data.
Description
FDR q-value
detection of chemical stimulus involved in sensory perception
1.27E-42
detection of chemical stimulus
6.29E-41
detection of chemical stimulus involved in sensory perception of smell
8.16E-41
detection of stimulus involved in sensory perception
3.18E-38
detection of stimulus
7.93E-31
G-protein coupled receptor signaling pathway
1.44E-21
sensory perception of smell
1.16E-19
sensory perception of chemical stimulus
4.86E-14
cell surface receptor signaling pathway
7.68E-7
sensory perception
7.02E-6
response to stimulus
5.47E-5
drug metabolic process
4.77E-3
signal transduction
1.12E-2
We performed DAVID’s functional classification analysis on genes with probes
exclusively selected from the promoter and genes with probes exclusively selected from the gene
body as previously described. 659 genes with MCC > 0.6 contained selected probes exclusively
from the upstream regions, resulting in 22 total clusters. 396 genes with MCC > 0.6 contained
selected probes exclusively from the gene body, resulting 23 clusters. For genes with selected
probes from the promoter (Table 2.8), cluster 2 contained genes involved with RNA splicing,
which is another mechanism by which other genes can be regulated. Similar to functional
clustering results on cell line data, cluster 4 contained genes coding ribosomal proteins and
cluster 1 and 5 contained transcriptional regulation genes. For genes with probes selected from
the gene body (Table 2.9), clusters 1 and 3 had terms involved with protein regulation and cluster
2 contained genes involved with nucleotide-binding. For both the cell line and TCGA data for
genes with selected gene body probes, chromodomain helicase and GTP-binding clusters were
observed.
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Table 2.8. Functional clusters of genes with MCC > 0.6 with upstream probes selected by
1NN-SFS algorithm in TCGA data.
Cluster
number
1

Number
of genes
5

Enrichment

Top terms (pval)

4.73

2

24

4.08

3

13

2.48

4

11

2.25

5

134

2.2

6

13

2.03

7

5

1.84

8

9

1.68

9

9

1.4

10

6

1.17

11

4

1.13

12

4

1.09

13

19

1.02

Nucleolus (8.8E-6), nuclear
lumen (1.6E-4), intracellular
organelle lumen (3.7E-4)
RNA splicing (1.0E-29), RNA
processing (8.0E-29), mRNA
processing (1.1E-28)
Cytoskeleton (1.5E-18),
cytoplasm (7.2E-10),
microtubule cytoskeleton
(4.7E-9)
Ribosomal protein (6.3E-21),
ribonucleoprotein (3.5E-19),
ribosome (1.5E-18)
Transcription regulation
(1.9E-45), zinc (4.1E-45),
transcription (1.3E-43)
Ubl conjugation pathway (1E19), modification-dependent
protein catabolic process (3E17), modification-dependent
macromolecule catabolic
process (3E-17)
Repeat: ANK1 (2.1E-8),
repeat ANK2 (2.1E-8), ank
repeat(2.4E-8
Mitosis (5.8E-17), cell
division (1.1E-15), nuclear
division (4.3E-15)
Repeat:WD3 (1.2E-15),
repeat:WD 2 (1.6E-15),
repeat: WD1 (1.6E-15)
Kelch repeat (1.7E-10),
repeat:Kelch 4 (8.2E-10),
repeat:Kelch 1 (8.7E-10)
Aminoacyl-tRNA synthetase
(7.7E-9), tRNA
aminoacylation (3.7E-8),
amino acid activation (3.7E-8)
Protein tyrosine phosphatase
(1.1E-7), protein tyrosine
phosphatase, active site (1.5E7), protein tyrosine
phosphatase activity (5E-7)
Transport (7.2E-14),
mitochondrial envelope (4.3E13), mitochondrion (5.8E-13)

Other representative
terms and notes
Transcription, DNAdependent (4.3E-2)
Spliceosome (6.8E-23),
rna-binding (2.3E-10)

Group of genes coding
for mitochondrial
ribosomal proteins
Transcription regulation

Ubiquitin proteins,
proteolysis (4.7E-14)

Ankyrin proteins

WD containing proteins

tRNA synthetases

Protein tyropsine
phosphatases
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Table 2.9. Functional clusters of genes with MCC > 0.6 with gene body probes selected by
1NN-SFS algorithm in TCGA data.
Cluster
Number

Number
of genes

Enrichment

Most significant terms (pval)

Other representative
terms (p-val) and notes

1

4

3.3

Rho GTPases

2

5

2.5

3

17

2.14

4

5

1.86

5

5

1.59

6

4

1.59

7

4

1.41

8

5

1.26

9

8

1.18

10

4

1.17

GTPase activation (5.5E-7),
domain:PH (1.9E-6),
Pleckstrin homology (4.5E6)
Atp-binding (2.2E-5),
nucleotide-binding(5.9E-5),
adenyl ribonucleotide
binding (1.8E-4)
Protein kinase – core (8.7E23), kinase (2.7E-21),
protein kinase – atp binding
site (1.2E-20)
Zinc (1.7E-4), metal-binding
(5.7E-4), zinc ion binding
(1E-3)
GTP-binding (8.4E-8),
guanyl nucleotide binding
(7.4E -7), guanyl
ribonucleotide binding
(4.7E-7)
Guanine nucleotide
dissociation stimulator,
CDC24, conserved site
(5.2E-8), Dbl homology
(DH) domain (6.8E-8), Rho
guanyl nucleotide exchange
factor activity (1.8E-7)
EGF-like, type 3 (1.6E-6),
egf-like domain (1.7E-6),
EGF-like (1.7E-6)
DNA/RNA helicase (4.7E8), domain:Helicase Cterminal (6.4E-7),
Helicase:ATP-binding
(7.4E-7)
Repeat:WD 3 (9.1E-14),
repeat:WD2 (1.2E-13),
repeat:WD1 (1.2E-13)
Nucleoplasm (3.3E-4),
transcription regulation
(1.2E-3), transcription (1.2E3)

Phosphorylation (1.9E20), nucleotide-binding
(1.9E-15), transferase
(7.3E-16)

Regulation of apoptosis
(2.1E-4)

Chromodomain helicases

WD containing proteins

2.4. Conclusions

We developed an algorithm, which utilizes different classification and regression
methods to select DNA methylation probes from the Illumina Infinium HumanMethylation450
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BeadChip Kit array that are most relevant to expression of their corresponding gene. We tested
the algorithms based on their ability to predict up/down expressed samples. We found that the
1NN-SFS algorithm performed the best compared to other methods tested (Fig. 2.1-2.3) and
random selection (Fig. 2.1). We demonstrated that this algorithm led to consistent results (Fig.
2.6). The 1NN-SFS has the advantages of selecting a certain number of probes as opposed to
ranking the probes.
We also observed that genes whose expression was predicted by DNA methylation with
high accuracy were enriched in GO terms related to the regulation of various biological processes
in both datasets. The overlap between highly predicted genes in both datasets was also
significantly higher. Genes whose expression was accurately predicted by DNA methylation may
be more sensitive to changes in DNA methylation. Therefore, genes that are sensitive to changes
in DNA methylation may be more likely to be involved in the regulation of various biological
processes.
Additionally, functional clustering revealed that many genes that were sensitive to DNA
methylation were regulators of other genes and proteins through a variety of mechanisms
including DNA-binding, protein kinase activity, protein degradation and protein synthesis. These
results suggest that these functions may answer how genes under the control of DNA methylation
regulate the various biological processes. There were no significant differences in function
between genes with gene body probes selected and genes with upstream probes selected. This
suggests that genes under the control of DNA methylation are more likely to be a regulatory gene
regardless of the genomic position of the most predictive DNA methylation.
To verify results on cell line dataset, we also applied 1NN-SFS on a breast cancer dataset
obtained from TCGA. The overall prediction accuracy in breast cancer data was lower than the
accuracy in cell line data (Fig. 2.1 and 2.7). This could be due to the heterogeneity of the tissue
samples. The expression of the tissue samples might be affected by other factors such as copy

47
number alteration and mixed cell population in the tissues. On the other hand, cell line data
contain more homogenous cells in each sample.
These methods will help researchers evaluate which probes are most involved in gene
expression and which genes are sensitive to changes in DNA methylation. Future work should be
aimed at studying other DNA methylation platforms to find the best methods for choosing regions
of where DNA methylation has a significant impact on gene expression. The ideas in this paper
could be extended to bisulfite sequencing and other commonly used platforms. Methylation-seq
data could work if the data is converted to segment data. Additionally, the combinatorial effects
of DNA methylation in different regions on gene expression can be studied with approaches
similar to methods here.
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CHAPTER 3

ProcessDriver: A computational pipeline to identify copy number drivers and associated
disrupted biological processes in cancer

A manuscript on the project described in this chapter was submitted to a peer-reviewed journal.

Abstract: Copy number amplifications and deletions that are recurrent in cancer samples harbor
genes that confer a fitness advantage to cancer tumor proliferation and survival. One important
challenge in computational biology is to separate the causal, driver genes from passenger genes in
large, aberrated regions. Many previous studies focus on the genes within the aberration (i.e., cis
genes), but do not utilize the genes that are outside of the aberrated region and dysregulated as a
result of the aberration (i.e., trans genes). We propose a computational pipeline, called
ProcessDriver, that prioritizes candidate drivers by relating cis genes to dysregulated trans genes
and biological processes. ProcessDriver assumes that a driver cis gene should be closely
associated with the disrupted trans genes and biological processes, as opposed to previous studies
that assume a driver cis gene should be the most correlated gene to the copy number of an
aberrated region. We applied our method on breast, bladder and ovarian cancer data from the
TCGA database. Our results included previously known driver genes and cancer genes, as well as
potentially novel driver genes. Additionally, many genes in the final set of drivers were linked to
new tumor events after initial treatment using survival analysis. Our results highlight the
importance of selecting driver genes based on their widespread, downstream effects in trans.

3.1. Introduction

Copy number amplifications and deletions that are recurrent in cancer samples harbor
driver genes that confer a fitness advantage to cancer tumor proliferation and survival (Hanahan
and Weinberg, 2001). Passenger genes that do not have a selective advantage are amplified or
deleted along with the drivers due to their proximity to the driver and as a result, have similar
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changes in expression with respect to copy number. Due to their similar copy number and
expression profiles, separating drivers from passengers is an important and difficult challenge.
One of the tools to compute significant recurrent copy number alterations in a given set
of samples is GISTIC. GISTIC relies on copy number data to detect regions of the genome that
harbor likely drivers (Mermel et al., 2011; Beroukhim et al., 2007). GISTIC leveraged the notion
that a region containing a driver gene should be altered significantly more than expected by
chance. This method has proven useful in identifying regions that likely harbor candidate driver
genes. However, it is difficult to distinguish passengers from drivers in large regions based on
copy number data alone.
Some studies have integrated copy number and gene expression data to determine the
effects of copy number on gene expression for genes within a copy number aberration, known as
cis genes (Tamborero et al, 2013; Ambatipudi et al., 2011; Fan et al., 2012; Pickering, et al.,
2013). The underlying assumption is that driver genes will have a more altered expression due to
a copy number aberration than passenger genes. For example, Oncodrive-CIS is a method to
score the cis genes as drivers by comparing the gene expression of samples with the aberration to
the gene expression of samples without the aberration (Tamborero et al., 2013). The strength of
the correlation between copy number and gene expression is also used to detect drivers (Fan et al,
2012; Pickering et al., 2013).
Some studies have identified drivers by considering the wider impact of a driver on
downstream target genes located outside of the aberration, known as trans genes. For instance,
Akavia et al. had the underlying assumption that copy number influences the driver gene
expression, which in turn alters the expression of a group of downstream, trans genes (2010).
Aure et al. determined which cis genes were highly correlated to their own copy number (2013).
The authors then determined which of these cis genes played a network perturbing role in cancer
through expression correlation to all other genes.
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Certain biological processes are known to be disrupted in cancer such as apoptosis and
cell cycle (Evan and Vousden, 2001). Therefore, identifying modules of cis and trans genes based
on biological processes would allow for additional insight into the specific biological processes
that the driver disrupts. Additionally, a driver cis gene changes the pathology of the cell and
therefore influences the expression of many other genes in trans. Therefore, the cis genes in the
module can also be narrowed down to a set of likely drivers based on the strength of the
association of the cis genes with the downstream trans genes, as opposed to the strength of a cis
gene’s association with its own copy number.
In this study, we propose a pipeline called ProcessDriver that detects driver cis genes,
associated trans genes and disturbed biological processes. We first find all of the differentially
expressed cis and trans genes with respect to an aberration. For a given aberration, the pipeline
creates modules of differentially expressed cis genes and differentially expressed trans genes
based on biological processes. The module is subject to further refinements to determine likely
drivers from the cis genes based on the relationship between cis gene expression and trans gene
expression. The pipeline is therefore able to determine which biological processes and trans genes
are dysregulated by the driver gene. We found that our selected drivers were more enriched in
cancer genes and were associated with a higher risk of new tumor events after initial treatment.
Additionally, consistent with previous studies, we found that the selected drivers were more
correlated with their own copy number.

3.2. Materials and Methods

3.2.1 ProcessDriver

We implemented a computational pipeline called ProcessDriver in R to compute
candidate copy-number driven driver genes by relating cis genes to dysregulated trans genes and
biological processes. ProcessDriver utilizes gene expression, copy number alteration data and GO
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database. ProcessDriver consists of two main steps, namely GO term enrichment step and driver
selection step. The entire pipeline of ProcessDriver is illustrated in Figure 1. In what follows, we
describe each main step of ProcessDriver. ProcessDriver is licensed under MIT License and
freely available upon request.

Figure 3.1. Flowchart of ProcessDriver. In the GO term association step, cis and trans genes that
were differentially expressed with respect to a copy number aberration were computed. Each cis
gene was associated with up to ten biological processes by performing a Kolmogorov-Smirnov test
using the correlation between the expression of the cis gene and every trans gene as a score. In the
driver selection step, a GO term module containing similar GO terms and associated cis and trans
genes was formed. The sparse CCA and multi-task LASSO were performed to narrow down
potential drivers of the biological processes in the module from the cis genes.

3.2.1.1. GO term enrichment step

The GO term enrichment step first identifies differentially expressed cis and trans genes for a
given aberration. Next, cis genes are associated with biological processes through the trans genes.
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A. Computing GISTIC regions and differential expressed genes on GISTIC regions

GISTIC 2.0 was used to detect significant recurrent somatic copy number alterations
(GISTIC regions hereafter) (Mermel et al., 2011). A GISTIC region with a log2 ratio above 0.1
was considered amplified, and a GISTIC region with a log2 ratio below -0.1 was considered
deleted. A confidence level of 0.75 was used to calculate the GISTIC region. The differential
expression analysis was performed using DESeq2 for each GISTIC region between samples with
no significant deletions or amplifications versus amplified or deleted samples (Love et al., 2014)
(p-value < 0.001). Genes were considered differentially expressed with respect to an aberration if
their adjusted p-value was less than .001 in DESeq2 in one or more of the GISTIC regions within
an aberration. Aberrations with greater than 50 differentially expressed genes were considered.
These are aberrations of interest suitable for our algorithm because of the widespread effects of
the aberration in trans, as well as the need to determine which cis genes are drivers. Batch effects
were taken into account using the TCGA batch IDs as a covariate in DESeq2.

B. Clustering GISTIC regions into aberrations

To account for co-occurring aberrations, GISTIC regions were clustered together such that
more similar regions were considered as a single aberration containing the individual GISTIC
regions. Throughout the rest of the manuscript, a cluster of GISTIC regions will be referred to as
an aberration. To cluster GISTIC regions into aberrations, a distance matrix was calculated where
each entry was 1 minus the Pearson correlation of the copy number of two different GISTIC regions
across all samples. Hierarchical clustering was performed on the distance matrix using average
linkage using the stats package in R and the resulting dendrogram was cut at half of the maximum
distance between the inter-cluster pairs.
The set of differentially expressed genes as determined by DESeq2 for each GISTIC
region within the aberration were pooled together. Aberrations with greater than 50 differentially
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expressed genes were considered. These are aberrations of interest suitable for our algorithm
because of the widespread effects of the aberration in trans, as well as the need to determine
which cis genes are drivers. For each aberration, a differentially expressed gene is hereafter called
cis gene if its chromosomal position was within a GISTIC region of that aberration, or called
trans gene otherwise.

C. Computing aberration-adjusted expression

In the remaining steps of ProcessDriver algorithm, we related expression changes between
cis genes and trans genes beyond the effects of copy number aberration. Both cis and trans genes
expression are potentially under the influence of the copy number aberration of interest to varying
degrees, and possibly other copy number aberrations in cis and trans. Due to the confounding
effects of copy number aberration on gene expression, correlation between all gene expression will
be high, making it difficult to establish relationships based solely on gene expression. To alleviate
these copy number effects on gene expression, we computed aberration-adjusted expression. First
we computed the variance stabilizing regularized log (rlog) transformation of the RNA-seq data.
Then we applied principal component regression (PCR) between a gene's expression as a response
and the copy number of all the GISTIC regions as predictors. The aberration-adjusted expression
was the residual expression after PCR. We chose the PCR method as it is a suitable model to address
the multicollinearity issue between the copy number of the GISTIC regions. All the remaining steps
in ProcessDriver used the aberration-adjusted expression data.

D. GO term association

To link cis genes in aberrations to possible dysregulated biological processes in trans,
each cis gene was associated with up to ten GO biological process terms through the trans genes.
For a given aberration, the correlation between each cis gene’s expression and each of the trans
gene’s expression in that aberration was calculated. A cis gene’s correlation to all trans genes was
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used as a score in a Kolmogorov-Smirnov (KS) test to determine significant GO terms using the
TopGO package in R (Alexa and Rahnenfuhrer, 2010). The KS test examined whether trans
genes annotated with a particular GO term were more correlated to the cis gene than trans genes
not related to that GO term. KS test repeated for each cis gene in each aberration and up to ten
GO terms with p-value < .05 were chosen to be associated with each cis gene.

3.2.1.2 Driver selection step

The driver selection step clusters cis and trans genes to form modules based on associated
biological processes. Next, expression data are utilized in a sparse canonical correlation analysis
to filter cis and trans genes with canonical correlation greater than 0.7. Finally, cis genes are
ranked as drivers using two multi-task LASSO-based methods.

A. Clustering of significant GO terms into GO term modules

Since some of the GO terms are semantically similar to each other and closely related in
the GO term hierarchy, for each aberration, the set of GO terms associated with the cis genes
were clustered using the getTermSim function with the relevance measure in the GOSim package
in R (Frohlich et al., 2007). For each GO term cluster, we defined GO term module as the
collection of cis genes that were significantly associated with at least one GO term in that GO
term cluster, and the trans genes that were annotated with at least one GO term in that GO term
cluster.

B. Applying sparse CCA to refine GO term modules

To further refine a GO term module to determine likely drivers, we performed sparse
canonical correlation analysis (SCCA) between the expression of p cis genes and the expression
of K trans genes (Witten et al., 2009). Let 𝑋𝑖𝑗 and 𝑌𝑖𝑗 be the expression for patient i for cis and
trans gene j, respectively. The goal of CCA is to maximize the canonical correlation between two
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groups of variables X and Y, by finding a linear combination 𝑌𝑢 and 𝑋𝑣 called canonical variates,
where 𝑢 = (𝑢1 , … , 𝑢𝐾 ), 𝑣 = (𝑣1 , … , 𝑣𝑝 ), are weight vectors (Hotelling, 1936).
𝜌=

𝑣 ′ 𝑋 ′ 𝑌𝑢

(3.1)

√𝑣 ′ 𝑋 ′ 𝑋𝑣√𝑢′ 𝑌 ′ 𝑌𝑢

SCCA maximizes this correlation while also applying penalties to u and v such that some
of the weights become zero resulting in q < p cis genes and M < K trans genes (Witten et al.,
2009).
If the canonical correlation was greater than 0.7, cis and trans genes that had non-zero
coefficients were left in the GO term module while those with zero coefficients were removed. If
the canonical correlation was less than 0.7, the module was no longer considered.

C. Applying multi-task LASSO to computer driver cis genes

Multi-task LASSO was performed with the expression of the remaining trans genes as a
response and the expression of the remaining cis genes as the predictors in order to rank the cis
genes based on their influence on trans gene expression. Let 𝑋 and 𝑌 now represent the remaining
q cis and M trans gene expression, respectively. Multi-task LASSO is the multi-response version
of LASSO (Friedman et al., 2010). Friedman et al., defines the multi-task LASSO model [Eq.
3.2] for q cis genes, M trans genes and N patients as:
𝑁

𝑞

𝑖=1

𝑗=1

1
min
∑ ||𝑌𝑖,1:𝑀 − 𝛽0 − 𝛽 𝑇 𝑋𝑖,1:𝑞 ||2𝐹 + 𝜆 ∑ ||𝛽𝑗 ||2
(𝑞+1)×𝑀
2𝑁
(𝛽0 ,𝛽)∈ℝ

(3.2)

In Eq. 3.2, 𝑌𝑖,1:𝑀 is a vector corresponding to the expression values of the trans genes in patient i
and 𝑋𝑖,1:𝑞 is the covariate vector of cis genes. 𝛽𝑗 is the jth row of the q x M coefficient matrix
corresponding to jth cis gene and 𝜆 is the tuning parameter controlling the strength of the penalty.
We ranked cis genes as drivers based on the order of appearance of each of the cis gene
predictors in the model as λ goes from largest to smallest. As λ gets smaller, more cis genes will
be non-zero and included in the model. The multi-task sharing portion involves which variables
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are selected. For each variable, a separate coefficient is fit for each response, resulting in the q +
1 x M coefficient matrix (Friedman et al., 2010). Therefore, for all the trans genes, the coefficient
for a given cis gene is either zero or non-zero, although the value of the non-zero coefficients will
vary between trans genes. Therefore, this ranking will be the same for every trans gene,
regardless of the non-zero coefficient value for the included cis genes
As an additional ranking system, the multi-task LASSO was rerun fifty times, each time
resampling 90% of the samples without replacement. For a single resample, the value of λ used
was the simplest model where the cross-validation error was within one standard error of the
minimum cross-validation error. The number of times a cis gene was selected out of fifty
resamples was used as a system to rank cis genes within the module. This ranking system would
identify potential drivers that are robust to sample variation.

3.2.2. Datasets to assess ProcessDriver

To assess the performance of ProcessDriver, we used Illumina HiSeq 2000 RNA
sequencing and level 3 segmented copy number inferred from Affymetrix Genome-Wide Human
SNP 6.0 copy number data were downloaded for 92 luminal A breast cancer samples, 120 ovarian
cancer samples and 120 bladder cancer samples from the TCGA repository (The Cancer Genome
Atlas Research Network, 2011, 2012, 2014).

3.3. Results

We downloaded RNA-seq and segmented copy number data from the TCGA repository
for 92 luminal A breast cancer, 120 bladder cancer and 120 ovarian cancer samples. We used
GISTIC 2.0 to identify recurrent copy number aberrated GISTIC regions using segmented copy
number data from each cancer type and clustered them into aberrations (see Materials and
Methods). For breast, ovarian and bladder cancer, 175, 116 and 156 GISTIC regions were
clustered into 66, 82 and 79 aberrations, respectively. DESeq2 was used to compute differentially
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expressed cis and trans genes for each aberration. Tables 3.1-3.3 contain information about the
cytoband locations and number of differentially expressed cis and trans genes for the aberrations
considered in each cancer type.

Table 3.1. Ovarian cancer co-aberrated regions. Amplified (Amp) and deleted (Del) regions in
each co-aberrated region with the number of cis genes and the number of trans genes.
Co-aberrated regions
Num cis
Num
trans
Amp 1q24.2, Amp 14q11.2, Del 3p25.1
40
49
Amp 3p12.3, Amp 19q13.42
31
20
Amp 8q24.21, Del 8p23.3
102
287
Amp 10p12.1, Amp 20q13.33
23
50
Amp 10q21.3, Del 6q27
9
49
Amp 11q14.1
14
64
Amp 12p13.2, Del 10p11.23
42
30
Amp 14q32.33, Del 9q34.3
56
13
Amp 19p13.12, Amp 19q12
75
48
Del 4p16.3, Del 4q13.2
64
69
Del 4q34.1
7
68
Del 5p15.2
19
74
Del 5q11.2, Del 5q13.2
33
44
Del 7p22.1, Del 11p15.4
113
147
Del 8p23.1, Del 12q23.1
23
140
Del 9p24.3, Del 9p11.2
43
24
Del 12p13.33, Del 12p13.2
37
17
Del 13q13.1, Del 13q14.3
50
71
Del 14q24.3, Del 16p13.3
147
77
Del 15q14
8
75
Del 16q23.1, Del 18q22.2
23
141
Del 17p11.2
6
114
Del 19q13.31, Del 19q13.41, Del 19q13.42
192
106
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Table 3.2. Bladder cancer co-aberrated regions. Amplified (Amp) and deleted (Del) regions in
each co-aberrated region with the number of cis genes and the number of trans genes.
Co-aberrated regions
Num cis
Num
trans
Amp 1q23.3, Amp 6p22.3, Amp 7p21.1, Amp 7p11.2,
26
137
Amp 10p14
Amp 3p25.2, Amp 8q22.3
43
540
Amp 7q31.1, Del 3p22.2, Del 3p14.2, Del 3p12.3
59
133
Amp 12q15, Amp 19q13.42
47
52
Amp 18p11.32, Del 16p13.3, Del 16p12.2
53
68
Del 2q34, Del 2q37.3
40
31
Del 5q11.2, Del 5q31.3
78
86
Del 6q12, Del 6q27, Del 14q24.3
95
141
Del 9p21.3, Del 9p11.2, Del 9q22.33
63
989
Del 11p15.4, Del 11p11.12, Del 11q25
31
78
Del 13q13.1, Del 13q14.2, Del 13q14.3
32
273
Del 15q13.2, Del 15q24.3
47
42
Del 17p11.2, Del 17p11.2, Del 17p11.2
16
69

Table 3.3. Breast cancer co-aberrated regions. Amplified (Amp) and deleted (Del) regions in
each co-aberrated region with the number of cis genes and the number of trans genes.
Co-aberrated regions
Num cis
Num trans
Amp 1p13.3, Amp 16q12.2, Del 1p13.3, Del 16q12.2
4
54
Amp 2p16.3, Amp 17q23.2, Del 4q34.1
26
126
Amp 5p15.2, Del 5p15.2, Del 5p15.1, Del 12q23.1
3
285
Amp 6p12.1, Amp 8p11.23
16
114
Amp 7p14.1, Del 7p22.1, Del 7q11.21, Del 7q34
15
112
Amp 8q12.1, Amp 8q12.3, Amp 8q22.1, Amp 8q23.3,
187
429
Amp 8q24.21, Del 8q11.21, Del 8q13.3, Del 8q24.3
Amp 9p11.2, Amp 9q34.3, Del 9q34.3
3
118
Amp 11p15.1, Amp 19q13.41, Del 1p36.11
8
43
Amp 12p13.2, Del 12p13.33, Del 12p13.2, Del 12p13.2 18
52
Amp 13q21.33, Del 13q13.1
25
52
Amp 14q24.3, Del 3p21.1, Del 14q24.3, Del 17p12
30
234
Amp 16p13.3, Amp 16p11.1
175
62
Amp 17q21.31, Del 11p11.12, Del 17q21.31
17
187
Amp 20q13.33, Del 15q24.3, Del 20q13.2, Del
76
243
20q13.33
Amp 22q11.23, Del 22q11.21, Del 22q11.23, Del
35
124
22q11.23
Del 2q11.2, Del 2q11.2, Del 17p11.2, Del 17p11.2
18
91
Del 11q14.3, Del 11q22.3
16
117
Del 16q22.1, Del 16q23.1
96
287
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For each cis gene in each aberration, associated dysregulated GO biological process
terms were computed (Section 3.2.1.1). For each aberration, GO term modules were formed
(Section 3.2.1.2A and then the cis and trans genes were filtered with SCCA (Section 3.2.1.2B).
Finally, the cis genes were ranked as likely drivers with two multi-task LASSO-based ranking
methods (Section 3.2.1.2C). The number of GO terms, and the average number of cis and trans
genes per module before and after SCCA are summarized in table 3.4.

Table 3.4. Number of modules and average number of cis and trans genes per module
before and after SCCA.
Breast cancer
Ovarian cancer
Bladder cancer
Number of modules
188
119
140
Average of number
11.6
12.1
10.9
of cis genes preSCCA
Average number of
6.1
5.6
6.4
cis genes after-SCCA
Average of number
35.1
21.7
39.5
of trans genes preSCCA
Average number of
17.3
11.3
19.2
trans genes afterSCCA

In the following sections, to evaluate the performance of ProcessDriver, we categorize cis
genes into various groups namely, multiple driver, driver, semi-driver, last in λ path, and filtered.
A driver gene is a cis gene that was selected 50 out of 50 times during resampling of multi-task
LASSO and appears as the first gene in the λ path in at least one GO term module. A multiple
driver gene is a gene that was selected as a driver in more than one GO term module. A cis gene
that is last in λ path is a gene that was selected last in λ path in every GO term module it appeared
in. A semi-driver was never selected as a driver gene, but was not last in λ path in at least one
module. A cis gene that in the filtered group was filtered because the canonical correlation of the
GO term module was < 0.7 (Figure 3.2) or its coefficient was 0 in a GO term module with
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canonical correlation > 0.7, and otherwise never appeared in the multi-task LASSO phase
(Section 3.2.1.2C).

Figure 3.2. Histograms of canonical correlations for GO term modules in (A) bladder cancer,
(B) breast cancer and (C) ovarian cancer.

For comparison purposes, we imitated some of the existing methods and selected drivers
based solely on the magnitude of correlation between their gene expression and their copy
number. For each GO module, cis genes with highest correlation between their expression and
copy number were selected as top correlated group. This group served to highlight the
differences between methods that consider the relationship between trans gene expression and cis
gene expression to select drivers and existing methods that selected drivers based on gene
expression correlation to cis copy number.

3.3.1. Multiple drivers are enriched in known cancer genes

Table 3.5 lists the entire multiple driver genes computed by ProcessDriver using breast
cancer data and Tables 3.6 and 3.7 lists the multiple driver genes in ovarian and bladder cancer,
respectively. For breast cancer, 19 out of 44 of the multiple driver genes were associated with
cancer in the literature using the tool OncoSearch (Lee et al., 2014), as one or more publications
describe their involvement in a cancer. Additionally, we found articles associating five more
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genes with cancer (Braig and Bosserhoff, 2013; Furic et al., 2012; Yamaguchi et al., 2014; Chen
et al., 2013; Jensen et al., 2014). Seven multiple drivers were known cancer genes in the AGCOH
or intOgen database (Huret et al., 2013; Gundem et al., 2010). Additionally, we used the
BioGRID database to find genes the multiple driver interacts with and then determined which of
the interacting genes are cancer genes in the AGCOH or intOgen database (Chatr-aryamontri et
al., 2015). Overall, 26 out of the 44 breast cancer multiple drivers are a likely cancer gene or
connected to a known cancer gene.

Table 3.5. Multiple driver genes associated with cancer in breast cancer. Number of articles
is the number of articles found with OncoSearch tool plus additional literature references found
manually. For cancer type (CT) column, BC – breast cancer, C – cancer, * indicates the multiple
driver is cancer gene in AGCOH or intOgen databases.
Gene

GO Terms

AURKA

mitotic cell cycle,
cell cycle
macromolecule
metabolic process,
RNA biosynthetic
process

SMARCB1

ADAM17
TRADD
CUL5
ELAC2
PSMA7
RBM5

COPS3
TBX21
APPBP2

ARFGAP1
BOP1

positive regulation
of cellular process
purine nucleoside
metabolic process
carbohydrate
metabolic process
cellular component
organization
mitotic cell cycle
process
cellular response to
endogenous
stimulus
Cellular component
organization,
T cell receptor
signaling pathway
cell cycle process,
cellular protein
localization
mitotic cell cycle
process
ribonucleoprotein
complex biogenesis

#
Articles
71

CT

Cancer gene interactions

BC*

59

C*

BRCA1, CDKN2A, TP53, CDC20, PLK1,
TACC1, NIN, CHFR
AKT1, ARID1A, ARID1B, ATM, BRCA1,
CCNE1, CREBBP, ING1, MLL, MLL3,
MYC, NCOR1, SIN3A, SMARCA4,
SMARCB1, TP53, XPO1, CDX2, GATA1,
RELB, SS18, XPC, MLLT10, MCPH1

32

BC

10

C

CASP8, CAV1, TNF, BCL10

6

BC

VHL, RNF7, RBX1

5

C*

CUX1

5

C

CUL1, EGFR, PLK1, TIMP2

5

BC*

4

C

2

C

COPS2, CUL1, CUL2, CUL3, HSP90AA1,
DDB1, PTGS2
CREBBP, EP300, GATA3

1

C

PCSK5, MLLT3

1

C*

1

C*
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DDT
HAGH
MED17

PTDSS1
RBM38
RRS1

DIDO1

EIF4ENIF1

DSCC1

AZIN1
BCL2L13
COG4

PSMD7

macromolecule
metabolic process
regulation of RNA
metabolic process
cellular response to
DNA damage
stimulus
G2/M transition of
mitotic cell cycle
regulation of protein
metabolic process
mitotic cell cycle,
regulation of protein
complex assembly
phosphorus
metabolic process,
phosphorylation
macromolecule
metabolic process,
RNA biosynthetic
process
mitotic cell cycle,
cell cycle phase
transition
cellular cation
homeostasis
gene expression,

1

C

1

C

1

C*

1

C

1

C

1

C

1

C

1

C

1

C

1

C

FANCA, FANCC

1

C

-

nucleobasecontaining
compound
metabolic process
cellular response to
DNA damage
stimulus

-

-

APC

-

-

PSMD11

BRCA1, SMARCA4, TP53, BARD1,
ESR2, GATA1, BRD4

HNRNPK, WWP1
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Table 3.6. Multiple driver genes associated with cancer in ovarian cancer. Number of articles
is the number of articles found with OncoSearch tool plus additional literature references found
manually. For cancer type (CT) column, OC – ovarian cancer, C – cancer, * indicates the multiple
driver is cancer gene in the OCGene databases.
Gene

GO Terms

CASP3

macromolecule
metabolic process,
single-organism
metabolic process
phosphorus metabolic
process, nitrogen
compound metabolic
process
heterocycle
biosynthetic process,
aromatic compound
biosynthetic process
regulation of
transcription, cellular
response to stress
cellular component
biogenesis, protein
complex assembly
cellular component
movement
organelle organization,
cellular component
assembly
protein modification
process
cell cycle, protein
modification process
lymphocyte activation,
response to cytokine
cellular metabolic
process
modificationdependent
macromolecule cat...
multicellular
organismal process
cell division, nuclear
division
biosynthetic process

RAF1

XRCC1

ALKBH1

NUMB

ARHGAP
35
SPTLC2

MRPL36
UTP20
GSDMD
PHRF1
PWP1

DACT3
RFC3
STK33

#
Articles
492

CT

Cancer gene interactions

OC*

192

C*

19

C*

MCL1, BIRC2, BIRC3, CTTN, BIRC5,
MAP3K14, BCL2, DCC, CASP10, CASP8,
CFLAR, HSPD1, HSPE1, BIRC7, CASP3,
XIAP
PRKCZ, SFN, PRKG1, BIRC2, BIRC3,
HRAS, PAK1, RRAS2, KRAS, PEBP1,
RB1, SPRY2, AKT1, MAP2K1, MAPK3,
RBL2, MAPK7,…
CHD1L, PARP1, APEX1, PARP2, LIG3,
TP53, PCNA, OGG1, POLB

14

C

-

2

C

MDM2, TP53, NOTCH1, L1CAM

2

C

RHOA

2

C

-

1

C

-

2

C

-

1

C

-

1

C

-

1

C

-

1

C

-

1

OC*

PCNA

1

C

-

SNW1

cellular response to
stress

1

C

MRPS31

macromolecule
catabolic process,
response to organic
substance

-

*

MEN1, VDR, RB1, SMAD3, RBL2,
SMAD4, NOTCH3, NCOA1, RBL1,
ASCC2, SKIL,…
EIF6

-

-

VDR, ESR2, MED1, MED25, ESR1

MED6
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Table 3.7. Multiple driver genes associated with cancer in bladder cancer. Number of articles
is the number of articles found with OncoSearch tool plus additional literature references found
manually. For cancer type (CT) column, BC – bladder cancer, C – cancer, * indicates the multiple
driver is cancer gene in AGCOH or intOgen databases.
Gene

GO terms

DEK

mitotic cell cycle,
cell cycle phase
transition
ribonucleoside
monophosphate
metabolic process,
DNA repair
epithelial cell
proliferation,
nucleoside
monophosphate
catabolic process
cellular response to
stress
cellular protein
modification
process
RNA metabolic
process
DNA metabolic
process
viral process,
symbiosis
macromolecule
localization

PPARG

VHL

HSPA9
SDHC

NUMB
FANCC
ERH
SNW1

DRG2

ANP32B

FEM1B
ARPC2

CAB39L
SYNJ2BP

HARS
MED6

Num
Articles
15

CT

Cancer gene interactions

BC*

-

214

C*

CREBBP, EP300, HDAC3, MED24,
NFE2L2, RB1, PML, NCOA4, NCOA3

244

C*

ATM, CUL2, EP300, FN1, HDAC3,
IREB2, RASGRP1, TP53, RHOC, CSTB,
FSCN1, RBX1

14

C

TP53

6

C*

-

2

C

MDM2, NOTCH1, TP53, L1CAM

1

C*

1

C

HSP90AA1, HSPA8, SPTAN1, FANCA,
FANCE, FANCF, FANCG
HSPA8, SETDB1, TP53, SH3GL2

1

C

cellular protein
localization,
regulation of
transcription from
RNA polymerase
DNA-dependent
DNA replication,
RNA splicing
single-organism
cellular process
cellular nitrogen
compound
biosynthetic process
mitotic cell cycle
process
protein modification
by small protein
conjugation
translation

1

C

MEN1, MLL, MYC, NCOR2, NOTCH1,
RB1, SIN3A, SMAD2, SMAD4, NOTCH3,
RBL2
-

1

C

-

1

C

-

1

C

CDH1, CTTN

1

C

STK11

1

C

ACVR2A

-

-

EEF1B2

cellular response to
stress

-

-

ESR2
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For ovarian cancer, 18 out of 33 multiple driver genes were associated with cancer
through the literature or an interactor with a known cancer gene. Articles for nine genes were
found with Oncosearch and supporting literature was found for seven more (Saeki et al., 2009;
Ettahar et al., 2013; Honoré et al., 2002; Jiang et al., 2008; Shen et al., 2014; Scholl et al., 2009;
Sato et al, 2015). The remaining two were found to have interactions with known cancer genes in
the OCGene ovarian cancer database (Liu et al., 2015). For bladder cancer, 17 out of 26 multiple
driver genes were a likely cancer gene or an interactor with one. Eight drivers had articles found
by OncoSearch and supporting literature was found for seven more (Sato et al., 2015; Xu et al.,
2016; Yang et al., 2016; Subauste et al., 2010; Rauhala et al., 2013; Choi et al., 2016; Lui et al.,
2016). The remaining two had interactions with known cancer genes in the AGCOH or intOgen
databases (Huret et al., 2013; Gundem et al., 2013).
Our methods associated cis genes with disrupted biological process in trans. Many of the
multiple driver genes in all three datasets were appropriately associated with biological processes
that they are known to be involved in. For example, in breast cancer, BOP1 is required for the
maturation of ribosomal RNAs (Lapik et al., 2004) and was associated in our algorithm with
“ribosome biogenesis” (Table 3.5). In ovarian cancer, candidate GSDMD is involved in the
release of Interleukin 1-Beta, and was associated with out methods with “lymphocyte activation”
and “response to cytokines” (Table 3.6). HSPA9 in bladder cancer is a heat shock protein and was
associated “cellular response to stress” (Table 3.7). These genes and others are all involved in
cancer, and are candidate copy number drivers and respective candidate disrupted processes.
In order to compute the enrichment of cis gene categories in known cancer gene lists, we
created a list of cancer genes by combining 727 known cancer genes from the AGCOH database
(Huret et al., 2013) and 475 known cancer genes from the intOgen database (Gundem et al.,
2013). The overlap between all cis genes and the cancer gene list in ovarian cancer was poor
(hypergeometric p -value = 0.28). Thus, for ovarian cancer, we used a more specific cancer list
from the OCGene ovarian cancer database (Liu et al., 2015). The OCGene ovarian cancer

66
database had a stronger, but marginal overlap with the cis genes (hypergeometric p-value = 0.09).
Cis genes in breast and bladder cancer had sufficient overlap with the intOgen and AGCOH
database (p-value = 0.0025 for bladder and 0.11 for breast cancer). We found that drivers and
multiple drivers had lower p-values than genes that were filtered out by ProcessDriver and cis
genes that were the most correlated with their own copy number (Table 3.8). Although some of
the p-values were marginal, the enrichment for drivers and/or multiple drivers was higher than for
cis genes that were filtered out. The marginal p-values could be due the incompleteness of the
databases. As shown in Table 3.5-3.7, additional literature was found via a manual search for
some multiple drivers supporting their involvement in cancer, despite not being present in the
databases, yet.

Table 3.8. Enrichment of cis genes with known cancer genes. Hypergeometric p-values for the
enrichment of known cancer genes in selected drivers, cis genes that were filtered out by
ProcessDriver, and cis genes that were the most correlated with their own copy number.
Multiple
Driver
SemiTop Cor
Last in λ Filtered
Bladder
Cancer
AGCOH,
IntOgen

Breast
Cancer
AGCOH,
IntOgen

Ovarian
Cancer
OCGenes

Driver
(26)
0.06

(89)

Multiple
Driver
(44)
0.01

Driver
(116)

Multiple
Driver
(33)
0.25

Driver
(82)

0.12

0.15

0.07

Driver
(197)
0.86

path (43)

(197)

(120)

0.52

0.77

0.6

SemiDriver
(266)
0.96

Last in λ
path (51)

Filtered
(259)

Top Cor
(128)

0.19

0.27

0.52

SemiDriver
(184)
0.35

Last in λ
path (45)

Filtered
(398)

Top Cor
(138)

0.71

0.85

0.8

3.3.2. SCCA filters cis genes with a lower correlation of expression to their own copy
number

The underlying assumption in many previous studies on cancer drivers is that driver gene
expression has a higher correlation to their own copy number than passenger genes (Tamborero et
al., 2013). Although we did not use correlation of cis gene expression to its copy number to
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narrow down likely drivers, we expect that our drivers would have a higher correlation between
their gene expression and copy number than the correlation of other genes’ expression to their
own copy number. Figure 3.3. illustrates the distribution of the correlation of cis copy number to
gene expression in the different groups of cis genes for bladder and breast cancer data and Figure
3.4. shows the same distribution for the ovarian cancer data. Cis genes that were filtered by
SCCA had a significantly lower average correlation of expression with copy number than driver
genes in all three cancers (Wilcoxon rank-sum p-value < 0.001 for ovarian and breast cancer and
< 0.05 for bladder cancer). We also observed that for cis genes filtered by SCCA, there were still
genes with extremely high correlation between expression and copy number. These results
suggest that utilizing correlation between gene expression and copy number to select potential
driver genes could make false positive selections.

Figure 3.3. Correlation of copy number to cis gene expression. Violin plots representing the
correlation of cis genes to their own copy number for selected drivers and cis genes filtered-out
by ProcessDriver for (A) bladder cancer and (B) breast cancer. Definition of each group is in the
results section. Asterisk indicates p < 0.05 in a Wilcoxon rank-sum test compared to the drivers
group.
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Figure 3.4. Correlation of copy number to cis gene expression in ovarian cancer. Violin plots
representing the correlation of cis genes to their own copy number for selected drivers and cis
genes filtered-out by ProcessDriver. Asterisk indicates p < 0.05 in a Wilcoxon rank-sum test
compared to the driver group.

3.3.3. Driver genes are associated with a higher risk of new tumor events after initial
treatment

In order to evaluate if the driver genes could predict new tumor events after initial
treatment, we performed survival analysis on cis genes. We fit a univariate Cox proportional
hazard model for each cis gene for the number of days to a new tumor event after the initial
treatment and used the cis gene expression as a covariate. If a patient did not experience a new
tumor event after the initial treatment, the days until the last follow-up were used and the patient
was censored. In the bladder cancer cohort, 97 out of 120 patients have had new tumor events
after the initial treatment and in the ovarian cancer cohort 86 out of 120 patients have had new
tumor events. Only two out of 92 of the luminal A patients had new tumor events after initial
treatment, therefore luminal A was not included in this analysis.
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A hazard ratio > 1 implies that an increase of expression of the cis gene increases the risk
of a new tumor event, while a hazard ratio < 1 implies that an increase of the cis gene expression
decreases the risk of a new tumor event. Overall in bladder cancer, drivers had hazard ratios
greater than one (Figure 3.5A). We compared the mean of the hazard ratios of each group using
the Wilcoxon rank-sum test. We observed that the mean of the hazard ratios was significantly
higher in the driver group compared to the top correlated, filtered and last in λ path groups with p
< 0.05.

Figure 3.5. Hazard ratios for new tumor events in a univariate Cox proportional hazards
model. Violin plots of hazard ratios for genes filtered out or selected at various stages of the
driver selection step for (A) bladder cancer and (C) ovarian cancer. Asterisk indicates p < 0.05 in
a Wilcoxon rank-sum test in bladder cancer and F-test of variances in ovarian cancer compared to
the driver group. Hazard ratios were plotted for genes in the multi-task LASSO stage against the
number of times they were selected by resampling and the rank in the λ path for (B) bladder
cancer and (D) ovarian cancer.

70
In ovarian cancer, multiple driver RAF1, a putative oncogene, had the highest hazard
ratio of 3.2. However, multiple driver CASP3, which promotes apoptosis and is in a deleted
region, had the lowest hazard ratio of 0.55. This highlights that the hazard ratio could be
dependent on the drivers oncogenic or tumor suppressor activities since a lower hazard ratio
implies lower risk with increased expression. We found that the driver group (𝜎 2 = 0.16) had a
significantly higher variance than the top correlated (𝜎 2 = 0.07), and filtered (𝜎 2 = 0.055)
groups (Levenne’s test p-value < 0.05). Although not significant, drivers also had a larger
variance than the last in λ path group. This suggests that drivers of ovarian cancer have a higher
or lower hazard ratio due to tumor suppressor and oncogenic activities (Figure 3.5C).
Bladder cancer also contains drivers with low hazard ratios. For example, multiple driver
FEM1B has a hazard ratio of 0.8 and is a pro-apoptotic protein (Subauste et al., 2010). Figure
3.5B and 3.5D illustrates the hazard ratio for new tumor events after initial treatment for cis genes
that appeared in the multi-task LASSO phase in bladder and ovarian data sets, respectively. The
results show that cis genes with the highest hazard ratios were selected close to 50 out of 50 times
during resampling and had a relatively low rank in the λ path.

3.4. Conclusions

We designed and implemented ProcessDriver in three different cancer sets and found
consistently that the most likely candidate drivers are more enriched in known cancer genes. For
each dataset, more than half of the multiple drivers are known to be involved in cancer.
Biological processes are associated with each driver through the trans genes, and all the trans
genes are differentially expressed as a result of the aberration. Therefore, the processes associated
with a driver are the ones that are likely disrupted.
We also found that the selected drivers have more extreme hazard ratios for new tumor
events after initial treatment with respect to new tumor events compared to cis genes filtered out
by ProcessDriver and cis genes selected based on their correlation of expression to their own
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copy number. Since drivers promote tumorigenesis, it is expected that drivers would be linked to
new tumor events.
Aside from ensuring that all cis genes and trans genes are differentially expressed with
respect to an aberrated region, we do not use the correlation of copy number to cis gene
expression in our filtering of drivers. However, as expected, the cis genes that were selected as
drivers had expression that was more correlated to their own copy number compared to cis genes
filtered by SCCA. This result suggests that drivers tend to have higher correlation to copy
number. However, when we selected the cis genes that are most correlated to their own copy
number for each GO term module, it results in a lower enrichment of known cancer genes and
lower hazard ratios with respect to new tumor events compared to drivers selected by
ProcessDriver. These results highlight the importance of selecting drivers based on the
relationship between cis gene expression and trans gene expression, as opposed to selecting the
cis genes based on correlation to their own copy number as in previous studies (Tamborero et al.,
2013).
While a couple of studies relate cis genes to other genes in trans, our approach differs
from previous approaches in several ways. The statistical approaches outlined in this pipeline
strongly emphasize a close relationship between a potential driver and downstream target trans
genes and provide insight into disrupted biological processes. Akavia et al. relates the expression
of cis genes to downstream targets, but does not integrate information about biological processes
(2013). Aure et al. associates cis genes with biological processes in trans. However, all other
genes are used as trans genes (2013). In this study, all trans genes must be differentially expressed
with respect to the aberration. In Aure et al., 2013 the correlation with cis genes to their own copy
number is to first narrow down cis genes. Here, we demonstrate that the relationship between cis
gene expression and trans gene expression is more valuable in selecting drivers than the
correlation of cis genes to their own copy number.
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ProcessDriver will narrow down a list of driver genes from many genes that are cisaffected by copy number. This could help find drivers which could be therapeutic targets of
drugs. Additionally, the algorithm associates drivers with biological processes through the trans
genes, which could aid in gaining insight into the widespread, downstream effects of the driver.
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CHAPTER 4

A Canonical Correlation Analysis Based Dynamic Bayesian Network Prior to Infer Gene
Regulatory Networks from Multiple Types of Biological Data

Reprinted with permission from JOURNAL OF COMPUTATIONAL BIOLOGY 22/4, published
by Mary Ann Liebert, Inc., New Rochelle, NY.

ABSTRACT
One of the challenging and important computational problems in systems biology is to infer gene
regulatory networks of biological systems. Several methods that exploit gene expression data
have been developed to tackle this problem. In this study, we propose the use of copy number and
DNA methylation data to infer gene regulatory networks. We developed an algorithm that scores
regulatory interactions between genes based on canonical correlation analysis. In this algorithm,
copy number or DNA methylation variables are treated as potential regulator variables and
expression variables are treated as potential target variables. We first validated that the canonical
correlation analysis method can infer true interactions in high accuracy. We showed that the use
of DNA methylation or copy number datasets leads to improved inference over steady-state
expression. Our results also showed that epigenetic and structural information could be used to
infer directionality of regulatory interactions. Additional improvements in gene regulatory
network inference can be gleaned from incorporating the result in an informative prior in a
dynamic Bayesian algorithm. This is the first study that incorporates copy number and DNA
methylation into an informative prior in dynamic Bayesian framework. By closely examining topscoring interactions with different sources of epigenetic or structural information, we also
identified potential novel regulatory interactions.
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4.1. Introduction

Gene regulatory networks (GRNs) are graphs where nodes represent genes and edges
represent regulatory interactions between genes. Several methods have been developed in fields
such as Bayesian statistics (Werhli and Husmeier, 2007), information theory (Margolin et al.,
2004, Bozdag et al., 2010) and regression (Setty et al., 2011) to infer GRNs.
Among the several methods to infer GRNs, the dynamic Bayesian network (DBN)
framework is a popular one because of its ability to handle noisy input data (Husmeier, 2003).
However, inference of networks based on time-series microarrays could be difficult because the
interactions are complex and there may be very few time points due to experimental limitations.
This has led to poor reconstruction of GRNs and a lack of scalability to more complex organisms.
More recent studies have attempted to integrate other sources of biological knowledge,
such as literature, protein-protein interactions and DNA binding data. One type of informative
prior was implemented in a variety of studies (e.g., Imoto et al., 2003; Werhli and Husmeier,
2007 and Zheng et al., 2011). This prior takes the form of a Gibbs distribution in which prior
information is encoded by an energy function. These studies have shown that informative priors
improve the inference of GRNs.
A few studies have integrated epigenetic and structural data types such as DNA
methylation, copy number and histone modification into various inference frameworks (Setty et
al., 2012; Zheng et al., 2011). Setty et al. (2012) used a regression-based framework to infer
regulatory programs, which after taking DNA methylation and copy number into account,
explains differential gene expression in terms of transcription factors and miRNAs. In Zheng et
al. (2011), the correlation of histone features was used as informative prior for a DBN-based
method.
Canonical correlation analysis (CCA) (Hotelling, 1936) has been used on a genome-wide
scale in combination with a penalization method to identify co-expressed or co-regulated genes
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and associated DNA markers (Waaijenborg et al., 2008). These studies have been successful in
identifying drivers of gene expression by their ability to reduce the number of variables. These
studies highlight the potential use of CCA for inferring GRNs.
In the present study, we developed a CCA-based algorithm to score potential regulatory
relationships in a set of genes. We used DNA methylation or copy number variables to represent
potential regulators, and expression variables to represent potential targets. We used the scores
from the CCA algorithm as a prior for a DBN-based algorithm (Werhli and Husmeier, 2007) to
infer GRNs in breast cancer tissues. Our algorithm is based on the assumption that changes to a
regulator's DNA methylation or copy number level will lead to corresponding changes in its
downstream targets. We investigated the use of the DBN method to improve the results of the
CCA algorithm. This is the first study that makes use of these data types in an informative prior
for the DBN framework.
We tested our algorithm to infer known GRNs in human based on a breast cancer dataset.
Our results showed that the CCA algorithm is able to infer GRNs with high accuracy. We also
showed that the DBN method could use the CCA results to obtain a higher accuracy.

4.2. Methods

4.2.1 Canonical correlation analysis based algorithm

We applied a CCA-based algorithm between DNA methylation or copy number and gene
expression datasets to compute potential regulatory interactions between genes. The brief
explanation of CCA is as follows. Consider a matrix X with q × p expression observations and a
matrix Y with q× p DNA methylation or copy number observations, where p is the number of
variables and q is the number of samples. Without loss of generality, we assume that the number
of variables and samples in each set is the same. CCA computes canonical variates, 𝛾 = 𝑌𝑢 and
𝛿 = 𝑋𝑣, 𝑢 = (𝑢1 , … , 𝑢𝑝 ), 𝑣 = (𝑣1 , … , 𝑣𝑝 ), where u and v are weight vectors that maximize the
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canonical correlation 𝜌 between X and Y (Equation 4.1). In this work, X and Y matrices were
generated using gene expression, DNA methylation and copy number datasets of 175 breast
cancer samples. We assumed that the variables that had higher weights would be more likely to
have regulatory interactions between each other.
𝜌=

𝑣 ′ 𝑋 ′ 𝑌𝑢
√𝑣 ′ 𝑋 ′ 𝑋𝑣√𝑢′ 𝑌 ′ 𝑌𝑢

(4.1)

We designed an algorithm to resample a small portion of the total set of genes iteratively
and applied CCA on this subset (Algorithm 1). At each iteration of resampling, we took a subset
of expression variables and a non-overlapping set of copy number or DNA methylation variables.
The copy number or DNA methylation variables represented potential regulators and the
expression variables represented potential targets. The two sets must be non-overlapping so that
large weights were not due to genes where DNA methylation or copy number was highly
correlated to their own expression (resulting in a false self-loop). We performed CCA between
the two subsets to compute weight vectors for both DNA methylation (copy number) and
expression variables. The top r out of p potential regulators were selected out of the weights in u.
Genes with large weights in the u vector were the most likely candidates to be regulators of some
or all of the p genes in the v vector. Genes with low weights in u were not potential regulators of
the set of selected genes in v.
We computed the regulatory interaction score by taking into account the absolute weight
of the regulator and target, as well as the canonical correlation of the canonical variate (Algorithm
4.1). The scores were continuously summed whenever the potential target and regulator pair were
selected together. The largest theoretical addition to the score per iteration could be one when the
potential target and potential regulator both had the maximum combination of weights and the
canonical correlation is one. After subsampling iterations were over, the score between each gene
pair was divided by the total number of times the pair was selected together to scale the score
between zero and one.

77

Algorithm 4.1: Scoring interactions based on CCA
n: number of genes, m: number of resamples, p: resampling subset size
S(j, k): interaction score between regulator j and target k
C(j, k): number of times, gene j was selected as regulator for gene k
for i =1:m
Select subset of methylation/copy number variables and subset of expression variables
Perform CCA between two subsets
Select weights u (methylation/copy number) and v (expression) that maximize canonical
correlation 𝜌
Select r top 80th percentile of weights in u
for j = 1:r
for k=1:p
(𝑎𝑏𝑠(𝑢𝑗 ) + 𝑎𝑏𝑠(𝑣𝑘 )) ∗ 𝜌
𝑆(𝑗, 𝑘) = 𝑆(𝑗, 𝑘) +
(𝑚𝑎𝑥(𝑎𝑏𝑠(𝑢)) + 𝑚𝑎𝑥(𝑎𝑏𝑠(𝑣)) )
𝐶(𝑗, 𝑘) = 𝐶(𝑗, 𝑘) + 1
𝑆
𝑆=
𝐶
The CCA computes weights for both regulator and target, and a canonical correlation.
The weight for the regulator could quantify the strength or relevance of the regulator to the
selected targets, and the weight of the target could quantify how much the target's expression is
affected. The canonical correlation could quantify strength of the association. We computed our
score by taking into account the weight of the regulator and target, as well as the canonical
correlation of the canonical variate.

4.2.2 Dynamic Bayesian network analysis

We implemented the DBN-based algorithm as described in Werhli and Husmeier, 2007.
We applied a Markov Chain Monte Carlo (MCMC) search heuristic with a Metropolis Hastings
acceptance criterion as described in Werhli and Husmeier, 2007. The prior (Equation 2.2) took
the form of a Gibbs distribution where prior information (results from the CCA algorithm) was
encoded by an energy function (Equation 2.3), where 𝑍(𝛽) was a normalizing constant. The
parameter, 𝛽, measured the influence of the prior information relative to the time series
expression data.
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𝑃(𝐺|𝛽) =

𝑒 −𝛽𝐸(𝐺)
𝑍(𝛽)

(4.2)

The energy function measured how closely the prior information matched with the
network structure at the current step of MCMC (Equation 4.3). In energy function, B is the prior
matrix, which was calculated by the CCA algorithm and G is the current network structure. As
the energy goes to zero, there is more agreement between the prior and the network structure.
𝑁

𝐸(𝐺) = ∑ |𝐵𝑖𝑗 − 𝐺𝑖𝑗 |

(4.3)

𝑖,𝑗=1

At each MCMC step, a move was made in which an edge was added or deleted. In this
method, the Metropolis Hastings acceptance criterion (Eq. 1.5) is expanded so that both the
network structure G and the hyperparameter 𝛽 can be sampled from the posterior distribution,
𝑃(𝐺, 𝛽|𝐷) (Wehrli and Husmeier, 2007):
𝑃𝑀𝐻 = min {

(𝑃(𝐷|𝐺𝑛𝑒𝑤 )𝑃(𝐺𝑛𝑒𝑤 |𝛽𝑛𝑒𝑤 )𝑃(𝛽𝑛𝑒𝑤 )𝑄(𝐺𝑜𝑙𝑑 |𝐺𝑛𝑒𝑤 )𝑅(𝛽𝑜𝑙𝑑 |𝛽𝑛𝑒𝑤 ))
}
𝑃(𝐷|𝐺𝑜𝑙𝑑 )𝑃(𝐺𝑜𝑙𝑑 |𝛽𝑜𝑙𝑑 )𝑃(𝛽𝑜𝑙𝑑 )𝑄(𝐺𝑛𝑒𝑤 |𝐺𝑜𝑙𝑑 )𝑅(𝛽𝑛𝑒𝑤 |𝛽𝑜𝑙𝑑 )

(4.4)

Hasting's ratio, 𝑄(𝐺𝑜𝑙𝑑 │𝐺𝑛𝑒𝑤 )/𝑄(𝐺𝑛𝑒𝑤 │𝐺𝑜𝑙𝑑 ), is equal to one as described in Section
1.2.3 of this dissertation and in Husmeier, 2003. 𝑅(𝛽𝑛𝑒𝑤 |𝛽𝑜𝑙𝑑 ) is the proposal distribution for the
hyperparameter. Based on the study by Werhli and Husmeier, Eq. 4.4 is broken up into two submoves of applying the acceptance criterion to a new graph structure, 𝐺𝑛𝑒𝑤 , while holding 𝛽 fixed:
𝑃𝑀𝐻 (𝐺𝑛𝑒𝑤 |𝐺𝑜𝑙𝑑 ) = min {1,

𝑃(𝐷| 𝐺𝑛𝑒𝑤 )𝑃(𝐺𝑛𝑒𝑤 |𝛽)𝑄(𝐺𝑜𝑙𝑑 |𝐺𝑛𝑒𝑤 )
}
𝑃(𝐷|𝐺𝑜𝑙𝑑 )𝑃(𝐺𝑜𝑙𝑑 |𝛽)𝑄(𝐺𝑛𝑒𝑤 |𝐺𝑜𝑙𝑑 )

(4.5)

And then sampling a new hyperparameter while holding G fixed:
𝑃𝑀𝐻 (𝛽𝑛𝑒𝑤 |𝛽𝑜𝑙𝑑 ) = min {1,

𝑃(𝐺|𝛽𝑛𝑒𝑤 )𝑃(𝛽𝑛𝑒𝑤 )𝑅(𝛽𝑜𝑙𝑑 |𝛽𝑛𝑒𝑤 )
}
𝑃(𝐺|𝛽𝑜𝑙𝑑 )𝑃(𝛽𝑜𝑙𝑑 )𝑅(𝛽𝑛𝑒𝑤 |𝛽𝑜𝑙𝑑 )

(4.6)

Assuming a uniform prior distribution and symmetric proposal distribution on the
hyperparameter, Eq 4.6 simplifies to:
𝑃𝑀𝐻 (𝛽𝑛𝑒𝑤 |𝛽𝑜𝑙𝑑 ) = min {1,

𝑃(𝐺|𝛽𝑛𝑒𝑤 )
}
𝑃(𝐺|𝛽𝑜𝑙𝑑 )

(4.7)
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This method can extend to incorporate multiple types of biological priors with their own
hyperparameters as described in Werhli and Husmeier, 2007. In our study, the MCMC procedure
was initialized, starting with an empty matrix, using a burn-in phase of 100,000 steps. Following
the burn-in phase, the network was sampled every 50 steps for another 100,000 steps.

4.2.3 Datasets

We obtained DNA methylation, copy number and gene expression datasets for 175 breast
cancer samples from the TCGA repository (The Cancer Genome Atlas, 2012). The datasets were
generated in Illumina Infinium 450k methylation array, Affymetrix Genome-Wide Human SNP
6.0 array, and Agilent mRNA expression array platforms, respectively. Additionally, for the DBN
algorithm, Affymetrix mRNA time-series data for MCF7 breast cancer cells were downloaded
from Nagashima et al. 2007, seven experiments with seven time points were used.
Batch effects were corrected for the mRNA expression data using the LIMMA package
in R (Smyth, 2005). For copy number, the normalized segmented means from TCGA were used
as the variables with no additional processing. We determined the segment each gene was located
within using the start and end sites of the gene provided by UCSC genome browser annotations
(Karolchik et al., 2014). Interactions between genes in the same copy number segment and from a
gene to itself were treated as uninformative prior for the DBN algorithm.
For the 450k DNA methylation data, each gene was associated with an average of 18
DNA methylation probes. We calculated the correlation between each probe and the expression
level of its associated gene. For every gene studied, we took the intensity of the top negatively or
positively correlated probe as a measure of the DNA methylation.

4.2.4 Networks and evaluation

We collected interactions of a subset of genes from the Human Transcription Regulation
Interaction (HTRI) database (Bovolenta et al., 2012) and the Transcription Regulatory Element
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Database (Zhao et al., 2005). These databases are composed largely of transcription factors that
bind near genes. We note that some transcription factor binding events do not result in expression
changes in a target gene. However, transcription factor binding is widely studied in humans. In
the absence of a gold standard, these TF-binding events are the most useful tool for identifying
interactions. Interactions found in either or both databases were included in our collection of
interactions (Table 4.1). We used this collection to assess the CCA- and DBN-based algorithm’s
ability to recall these interactions.

Table 4.1. Three networks used to assess the recall of regulatory interactions by CCA and
DBN.
Network
Genes in the network
# of
# of
name
genes interactions
GATA3
GATA3, ESR1, ETS1, FOXA1, FOXP3, MYC, SP1,
25
92
STAT1, TFAP2A, CDK2NA, TMEM2, PRDM4, MID2,
TEK, RBMS1, SERPINF1, EDN1, ATP2B1, PPARG,
VGLL4, APP, ATOX1, BTG2, STAT4, STX3
BRCA
CHEK2, MAP3K3, NEK2, BARD1, BRCA1, BRCA2,
22
32
FHIT, ESR1, ELK4, BCL2, STAT3, PCNA, POU4F2,
TP53, ELK1, ERG, DDB2, GADD45A, IGF1R, TAF10,
JAK1, JAK2
FOXA1
FOXA1, BCL2, BCL6, CDKN2A, FOXA3, STAT1,
20
32
STAT4, TRIM25, IRF1, GATA3, TP73, PRDM14,
STAT6, PCNA, CDKN1A, FASN, PTGS2, CCL17,
FCGRT, ICAM1

We ran the CCA algorithm on DNA methylation and copy number datasets
independently. The CCA algorithm computed an interaction score scaled between zero and one
for every gene pair in the network. We used CCA results as priors for the dynamic Bayesian
algorithm. We computed receiver operating characteristic (ROC) curves and the area under each
ROC curve (AUC) to assess the performance of the CCA and DBN algorithms. We counted
misdirected edges as false positives.
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4.2.5. Implementation

We implemented our tool in MATLAB. The foundation for the code written for this
study was made possible by the Bayes Net Toolbox (Murphy, 2002). Additionally, code obtained
from Husmeier, 2003 aided in the development by providing the MCMC portion of the algorithm.
The source code of this tool is freely available upon request.

4.3. Results and discussion

4.3.1 Computing regulatory interactions in breast cancer by utilizing the CCA algorithm

For each of the three networks studied, we computed the receiver operating characteristic
(ROC) curve and the area under the curve (AUC) for the CCA algorithm. The sensitivity is the
true positive rate (y-axis) and the inverse specificity is the false positive rate (x-axis). Therefore, a
larger AUC for an ROC curve indicates a greater number of correctly inferred edges between
genes relative to incorrectly inferred edges. We ran the algorithm using DNA methylation, copy
number and expression variables as regulator variables. The resampling step was iterated 10,000
times in which a subset of five variables was selected. Target variables were always expression
variables. Figure 4.1 A, B and C and Table 4.2 show that using DNA methylation variables as
potential regulators achieved higher accuracy than the accuracy obtained when copy number or
expression variables were used as potential regulators in GATA3 and FOXA1 networks. Copy
number based results performed best in BRCA network. Using expression variables as regulators
performed worst in all three networks. If expression is used on both sides of the canonical
correlation analysis, it may be more difficult to separate regulator from target. The DBN results
(Figure 4.1 D, E and F) are discussed in section 4.3.3.
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Figure 4.1. ROC curves for the CCA algorithm in A) GATA3, B) BRCA and C) FOXA1
networks and the DBN algorithm in D) GATA3, E) BRCA and F) FOXA1 networks.

Table 4.2. AUC for the networks presented in Figure 4.1.
GATA3

DNA
methylation
Copy number
Expression
Averaged
Uninformative
Both

BRCA

FOXA1

CCA

DBN

CCA

DBN

CCA

DBN

0.81

0.73 ± .01

0.68

0.74 ± .01

0.75

0.77 ± .01

0.64
0.62

0.67 ± .01

0.70
0.55

0.72 ± .01

0.67
0.60

0.69 ± .01

0.78

0.74 ± .01
0.60 ± .01
0.75 ± .01

0.75

0.78 ± .02
0.70 ± .01
0.75 ± .01

0.74

0.78 ± .01
0.60 ± .01
0.78 ± .02

We tested the convergence of the CCA algorithm by running the algorithm over 20,000
steps with five variables. Every 1,000 steps, we calculated the absolute difference between the
entries in the scoring matrix at the current step and the scoring matrix from 1,000 steps ago. We
then summed all of these differences. We find that the sum of the differences becomes relatively
small at around 2,000 steps. suggesting our algorithm converges quickly. Figure 4.2. shows the
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results for BRCA DNA methylation. Similar results were obtained for other datasets and
networks.

Figure 4.2. Convergence of CCA algorithm.

We also tested the algorithm using different subset sampling sizes. We found that in
general, sampling subset sizes between 3 and 5 lead to a higher increase in AUC (Table 4.3).
Table 4.3. Resampling subset size vs. AUC. Meth – DNA methylation, CN – Copy number,
Exp – Expression for regulators.
p
GATA3
BRCA
FOXA1
Meth
CN
Exp
Meth
CN
Exp
Meth
CN
Exp
3 0.77
0.65
0.64
0.7
0.69
0.6
0.74
0.63
0.62
4 0.77
0.65
0.65
0.7
0.69
0.6
0.74
0.66
0.63
5 0.81
0.64
0.63
0.68
0.7
0.55
0.75
0.67
0.6
6 0.76
0.62
0.6
0.6
0.62
0.55
0.68
0.68
0.6
7 0.7
0.6
0.59
0.55
0.56
0.55
0.65
0.68
0.55

Additionally, we modified the algorithm to resample one target and five regulators, and
then chose the best regulator(s) in the 80th percentile of weights. The formula for scoring the
algorithm was the same. We computed ROC curves for this method (Figure 4.3). The
performance with this modification was worse than the original algorithm. This result, in addition
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to the simple correlation approach, suggests that the ability to detect regulators may be amplified
by relating them to multiple targets. To test this, we modified our algorithm again to select one
regulator and five targets. Since there is only one regulator, we do not select the top 80th
percentile of weights. The rest of the algorithm remained the same. We again computed ROC
curves for this method (Figure 4.3). This approach performs very well in some cases, although
our original approach performs slightly better. This suggests that selecting top regulator(s) by
weight, in light of other potential candidates, contributes to the robustness of the algorithm.

Figure 4.3. CCA algorithm vs. algorithm performed with a single regulator and multiple
targets and the algorithm performed with a single target and multiple regulators.

Table 4.4. AUC for ROC curves in Fig.4.3.
GATA3
Meth
CN

BRCA
Meth

FOXA1
CN

Meth

CN

CCA Algorithm
0.81

0.64

0.68

0.70

0.75

0.67

0.76

0.64

0.62

0.60

0.69

.59

0.55

0.55

0.67

0.59

0.61

0.5

Multiple Targets
Multiple Regulators
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Additionally, we tested the hypothesis that methylation of a potential target establishes
directionality in the network, contributing to the overall better performance of methylation data
compared to expression data. We looked at interactions with only one direction. We subtracted
the score in the correct direction (CD) from the score in the incorrect direction (ID). Therefore,
positive directionality scores represent correct directionality, zero scores represent no
directionality and a negative score represent directionality in the wrong direction. Supplementary
Figure 4.4. shows the results for the GATA3, BRCA and FOXA1 network. We find that for the
GATA3 and FOXA1 networks, but not the BRCA network, the directionality score was
significantly more positive for DNA methylation data compared to expression data. This suggests
that the better performance of DNA methylation data may be due in part by its ability to establish
directionality.

Figure 4.4. Directionality in the CCA algorithm.

We calculated the correlation between the methylation state, copy number or expression
state of a potential regulator and the expression of a potential target individually. We took the
absolute value of the correlation as a score and computed an ROC curve and the corresponding
AUC for each network (Fig. 4.5 and Table 4.5). We found that in all cases, a simple correlation
performs worse than our algorithm. We note that using the DNA methylation level for potential
regulators performed better than the copy number or expression in the simple correlation
approach. This also suggests that DNA methylation data may be more useful in establishing
genetic relationships.
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Figure 4.5. ROC curves for correlation-based approach.

Table 4.5. AUC for ROC curves in Fig 4.5.
GATA3

BRCA

FOXA1

DNA methylation

0.64

0.64

0.64

Copy number

0.58

0.57

0.46

Expression

0.58

0.56

0.62

We tested for a significant separation of experimentally validated versus nonexperimentally validated genes. Figure 4.6 shows the CCA algorithm scores for interacting and
non-interacting pairs of genes in the GATA3 network and Figure 4.7 shows the scores for the
BRCA and FOXA1 networks. We observed that for DNA methylation and copy number datasets,
the CCA algorithm scores were significantly higher for interacting pairs compared to noninteracting pairs (Wilcoxon rank-sum test p < .001). This was not the case for the gene expression
datasets.
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Figure 4.6. Regulatory interaction scores by the CCA algorithm for interacting vs. noninteracting pairs in the GATA3 network using A) DNA methylation, B) Copy number and
C) Expression datasets as regulator variables.

Figure 4.7. Regulatory interaction scores by the CCA algorithm for interacting vs. noninteracting pairs in the BRCA and FOXA1 network using A) DNA methylation, B) Copy
number and C) Expression datasets as regulator variables.

4.3.2 Validation of false positive interactions of the CCA algorithm in literature

False positives are interactions that were scored high by the CCA algorithm, but were not
present in the databases. False positive interactions may represent unknown interactions since
interaction databases are often incomplete. Tables 4.6 and 4.7 show the top 15 scoring false
positive interactions computed by the CCA algorithm using DNA methylation and copy number,
respectively. In Table 4.6, several of the regulators are known to be affected by DNA methylation
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in cancer cells. Specifically, BCL2 has a hyper-methylation biomarker (Stone et al., 2013).
Inactivation of IRF1 via DNA methylation has been implicated in the tumorigenesis of gastric
cancers (Yamashita et al., 2010). TP73 is known to be controlled by promoter hypermethylation
(Dong et al, 2002). In Table 4.7, aberrant expression of ATOX1 has been recently linked to breast
cancer (Choong et al., 2010). IRF1 undergoes structural changes and has been linked to frequent
loss of heterozygosity in breast cancer (Cavalli et al., 2010). These results suggest that the
performance of a regulator may indicate the extent the regulator is affected by DNA methylation
and/or copy number abnormalities.

Table 4.6. Top 15 false positive interactions computed by the CCA algorithm utilizing DNA
methylation data.
GATA3

BRCA

FOXA1

Regulator

Target

Score

Regulator

Target

Score

Regulator

Target

Score

GATA3

ESR1

0.76

BCL2

ESR1

0.71

TP73

STAT4

0.7

FOXA1

ESR1

0.75

BCL2

IGF1R

0.70

BCL2

FOXA1

0.7

FOXA1

ETS1

0.71

BCL2

BARD1

0.68

IRF1

STAT4

0.67

GATA3

ETS1

0.69

BCL2

GADD45A

0.67

TP73

IRF1

0.65

ESR1

ETS1

0.68

BCL2

MAP3K3

0.67

IRF1

ICAM1

0.64

TFAP2A

STAT4

0.68

BRCA2

IGF1R

0.67

TP73

CCL17

0.62

APP

ESR1

0.67

BCL2

FHIT

0.66

BCL2

GATA3

0.61

ESR1

RBMS1

0.66

BCL2

PCNA

0.66

IRF1

FOXA1

0.61

FOXA1

FOXP3

0.65

BCL2

ERG

0.66

IRF1

CCL17

0.6

ETS1

ESR1

0.65

BCL2

CHEK2

0.66

TP73

ICAM1

0.58

GATA3

FOXP3

0.65

BCL2

DDB2

0.65

TP73

STAT1

0.57

FOXA1

MYC

0.64

BCL2

BRCA1

0.65

FOXA1

FCGRT

0.56

TFAP2A

ETS1

0.63

IGF1R

CHEK2

0.63

GATA3

PTGS2

0.56

TMEM2

ESR1

0.63

IGF1R

ESR1

0.62

BCL2

ICAM1

0.55

FOXA1

TEK

0.63

JAK1

ESR1

0.62

GATA3

FASN

0.55
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Table 4.7. Top 15 false interactions computed by the CCA-base algorithm utilizing copy
number data.
GATA3

BRCA

FOXA1

Regulator

Target

Score

Regulator

Target

Score

Regulator

Target

Score

SP1

FOXA1

0.58

STAT3

FHIT

0.49

IRF1

GATA3

0.62

ATOX1

GATA3

0.58

BRCA1

NEK2

0.46

STAT6

FOXA1

0.54

SP1

GATA3

0.55

GADD45A

JAK1

0.45

IRF1

FOXA1

0.54

ATOX1

ESR1

0.54

MAP3K3

BRCA2

0.45

IRF1

BCL2

0.5

SP1

ATP2B1

0.50

JAK2

BRCA2

0.41

STAT6

GATA3

0.48

SP1

RBMS1

0.48

GADD45A

ESR1

0.41

IRF1

FCGRT

0.45

ATOX1

FOXA1

0.48

STAT3

BRCA1

0.38

CDKN1A

GATA3

0.44

ATOX1

BTG2

0.48

BCL2

TAF10

0.36

IRF1

CDKN2A

0.43

SP1

PRDM4

0.48

ERG

ESR1

0.36

IRF1

STAT4

0.42

SP1

ATOX1

0.47

BRCA2

CHEK2

0.35

GATA3

FCGRT

0.41

GATA3

ESR1

0.47

ELK4

NEK2

0.35

GATA3

BCL2

0.41

ATP2B1

FOXA1

0.46

POU4F2

CHEK2

0.35

STAT6

TP73

0.41

SP1

BTG2

0.46

BRCA1

BARD1

0.34

IRF1

ICAM1

0.41

PRDM4

FOXA1

0.46

POU4F2

JAK1

0.33

IRF1

PCNA

0.41

FOXA1

ESR1

0.45

TAF10

DDB2

0.32

IRF1

TP73

0.41

The CCA algorithm computed interactions between IRF1 and BCL2, CDKN2A and
PCNA that are supported by literature (Saneau et al., 2000; Coccia et al., 1999; Frontini et al.,
2009). Interactions of SP1 with FOXA1, GATA3, and RBMS1 are also supported by our results
and by literature (Chavez et al., 2009; Gilli et al., 2004; Haigermoser et al., 1996). Tables 4.8 and
4.9. provide a complete summary of supporting literature.
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Table 4.8. Experimental validation for false positives inferred with DNA Methylation CCA.
Reg
GATA3
FOXA1

GATA3
Target
ESR1
ESR1

Ref
Bernard
o et al.,
2010

Reg

BRCA
Target

BCL2
BCL2

ESR1
IGF1R

FOXA1

ETS1

BCL2

BARD1

GATA3

ETS1

BCL2

ESR1

ETS1

BCL2

TFAP2
A
APP

STAT4

BRCA2

GADD4
5A
MAP3K
3
IGF1R

BCL2

FHIT

ESR1

ESR1
FOXA1

RBMS1
FOXP3

ETS1
GATA3

ESR1
FOXP3

FOXA1

MYC

TFAP2
A
TMEM2

FOXA1

Von
Arnim et
al., 2006

Wang
et al.,
2011
Ni et al.,
2013

BCL2
BCL2

PCNA
ERG

BCL2
BCL2

CHEK2
DDB2

BCL2

BRCA1

ETS1

IGF1R

CHEK2

ESR1

IGF1R

ESR1

TEK

JAK1

ESR1

FOXA1
Ref

Foulston
e et al.,
2013

Reg

Target

TP73

STAT4

BCL2

FOXA1

IRF1

STAT4

TP73

IRF1

IRF1

ICAM1

TP73

CCL17

BCL2

GATA3

IRF1

FOXA1

IRF1
TP73

CCL17
ICAM1

TP73

STAT1

FOXA1

FCGRT

GATA3

PTGS2

BCL2

ICAM1

GATA3

FASN

Ref
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Table 4.9. Experimental validation for false positives inferred with Copy Number CCA.
GATA3

BRCA

Reg

Target

Ref

Reg

Target

SP1

FOXA1

Chavez
et al.,
2009

STAT3

FHIT

ATOX1

GATA3

SP1

GATA3

ATOX1

ESR1

SP1

Gilli et
al., 2004

ATP2B1

SP1

RBMS1

Haigerm
oser et
al., 1996

BRCA1

NEK2

GADD4
5A
MAP3K
3

JAK1

JAK2

BRCA2

FOXA1
Ref

Wang et
al., 2004

Reg

Target

IRF1

GATA3

STAT6

FOXA1

IRF1

FOXA1

IRF1

BCL2

STAT6

GATA3

IRF1

FCGRT

CDKN1
A

GATA3

IRF1

CDKN2
A

BRCA2

GADD4
5A

ESR1

ATOX1

FOXA1

STAT3

BRCA1

ATOX1

BTG2

BCL2

TAF10

SP1

PRDM4

ERG

ESR1

IRF1

STAT4

SP1

ATOX1

BRCA2

CHEK2

GATA3

FCGRT

GATA3

ESR1

ELK4

NEK2
GATA3

BCL2

STAT6

TP73

IRF1

ICAM1

IRF1

PCNA

IRF1

TP73

ATP2B1

FOXA1

POU4F2

CHEK2

SP1

BTG2

BRCA1

BARD1

PRDM4

FOXA1

FOXA1

ESR1

POU4F2

Bernard
o et al.,
2010

TAF10

Rodriqu
ez et al.,
2004

JAK1

Ref

Saneau
et al.,
2000
Stocking
er et al.,
2007

Coccia
et al,
1999

Tsarovin
a et al.,
2010

Frontini
et al.,
2009

DDB2

4.3.3 Inferring GRNs by a DBN-based approach utilizing priors by the CCA-algorithm

We used the results from the CCA algorithm as a prior in the DBN algorithm. We first
analyzed the effect of the parameter, 𝛽, which is a measure of the agreement between the time
series data and the prior (Werhli and Husmeier, 2007) by holding 𝛽 constant throughout the
MCMC learning process. Table 4.10 shows the values of 𝛽 used and the AUC achieved after
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averaging 5 executions of the DBN algorithm using DNA methylation- and copy number-based
priors, respectively. In every case, except for GATA3 DNA methylation, the DBN improved the
overall accuracy for some values of 𝛽. DNA methylation tended to perform better with higher
values of 𝛽, while copy number tended to perform better at lower values for 𝛽.
Table 4.10. AUC for various values of 𝜷.
𝛽

GATA3

BRCA

FOXA1

Meth

CN

Meth

CN

CCA

0.81

0.64

0.68

1

0.64

0.60

3

0.68

5

Meth

CN

0.70

0.75

0.67

0.60

0.60

0.69

0.56

0.61

0.60

0.81

0.70

0.63

0.69

0.63

0.62

0.75

0.73

0.64

7

0.72

0.63

0.62

0.75

0.73

0.69

9

0.73

0.73

0.72

0.73

0.72

0.64

11

0.72

0.70

0.70

0.65

0.70

0.65

13

0.73

0.60

0.70

0.62

0.76

0.64

15

0.76

0.60

0.74

0.68

0.79

0.63

17

0.73

0.55

0.72

0.68

0.73

0.60

19

0.73

0.56

0.72

0.65

0.73

0.60

In the following experiments, we used 𝛽 as a hyperparameter as in Werhli and Husmeier
(2007). We used the CCA results on DNA methylation and copy number independently in two
DBN algorithm runs. We also used DNA methylation and copy number results as two separate
priors in a single DBN algorithm run. Finally, we averaged together the CCA results of DNA
methylation and copy number and used it as a single prior. For each network, results with an
uninformative prior were also obtained.
Figure 4.1 D, E and F shows the ROC curve for the DBN method, with the AUC reported
in Table 4.2. When the CCA results for DNA methylation or copy number were used as a prior,
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there were improvements in the AUC over just CCA alone. One exception was in GATA3
network in which DNA methylation-based prior had higher accuracy than in the DBN algorithm
with this prior. This was potentially due to limitations of time series expression data. The results
suggest that using the average prior or two priors leads to more improvement over using a single
prior alone. In order to compute significance of the DBN algorithm's improvement over the CCA
algorithm, we ran the CCA algorithm five times for each network for both DNA methylation and
copy number data. We then used each result as a prior in the DBN algorithm. We performed a
paired t-test between the AUC in the CCA algorithm results and the DBN algorithm results. We
found that the improvement of DBN was significant (< .05) in all cases except for GATA3
network results when utilizing DNA methylation data. We report the significance in Table 4.11.

Table 4.11. T-Test for DBN runs.
GATA3 Copy
BRCA Copy Number
Number
CCA
DBN
CCA
DBN

FOXA1 Copy
Number
CCA
DBN

0.64
0.64
0.64
0.64

0.66
0.66
0.66
0.67

0.68
0.68
0.68
0.70

0.72
0.73
0.72
0.70

0.67
0.68
0.67
0.66

0.69
0.70
0.70
0.68

0.64
p = .003

0.65

0.69
p = .02

0.72

0.67
p < .001

0.69

GATA3
Methylation
CCA
DBN

BRCA Methylation
CCA

DBN

FOXA1
Methylation
CCA
DBN

0.80
0.80
0.79
0.80

0.74
0.74
0.73
0.73

0.68
0.69
0.68
0.68

0.72
0.74
0.74
0.75

0.75
0.73
0.73
0.73

0.75
0.75
0.77
0.75

0.8

0.73

0.69
p < .001

0.74

0.74
p = .03

0.77
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4.3.4. Validation of false positives in literature for DBN

Tables 4.12 and 4.13 show the top 15 false positive interactions computed by the DBN
algorithm for each prior in GATA3 and BRCA networks, respectively. The FOXA1 network did
not have false positives that scored over 0.5 in multiple prior types. Some of these interactions
were supported by recent literature. In the GATA3 network, there are 15 interactions that were
supported by the results in at least two prior types. Among these, SERPINF1 PPARG has been
experimentally validated by Ho et al. (2007). This interaction is supported by 3 prior types.
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Table 4.12. Top 15 scoring false positive interactions in GATA3 network computed by the
DBN algorithm using various priors.
Regulator

Target

Two
priors

Average
prior

DNA
Methylation

Copy
number

EDN1

0.77

0.69

0.74

0.55

VGLL4
SERPINF1

SERPINF
1
TMEM2
PPARG

0.73
0.77

0.65
0.56

0.59
0.99

0.64

EDN1
RBMS1
RBMS1
GATA3
RBMS1
RBMS1

FOXA1
MID2
TFAP2A
ESR1
GATA3
APP

0.97
0.60
0.60
0.59
0.66
0.57

0.97
0.55
0.53
0.65

0.97
0.50
0.53
0.54
0.68
0.55

RBMS1
TFAP2A
SP1
ESR1
ATOX1
TMEM
FOXA1
MYC

ATOX1
STAT1
VGLL4
AT2B1
SP1
CDKN2A
FOXP3
CDKN2A

0.51
0.62
0.55
0.50
0.57
0.74
0.63
0.80

VGLL4
STAT1
CDKN2A
EDN1
APP
SP1
SERPINF1
PPARG

MID2
BTG2
STAT4
STAT4
ATOX1
STAT4
SP1
STAT1

0.79
0.78
0.72
0.69
0.67
0.67
0.65
0.64

MYC
RBMS1
STX
APP

ATP2B1
ESR1
CDKN2A
ATOX1

0.63

EDN1
RBMS1

STX3
VGLL4

Supporting
Data

Ho et al.,
2007

0.60
0.55
0.83
0.75
0.74
0.83
Zindy et al.,
1998

Ricote et al.,
1998
0.53
0.67
0.60

Martin et al.,
2008
0.52
0.49
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Table 4.13. Top 15 scoring false positive interactions in BRCA network computed by the
DBN algorithm using various priors.
Regulator

Target

PCNA
PCNA
PCNA
PCNA
BRCA2

CHEK2
DDB2
JAK1
JAK2
BRCA1

ESR1
BRCA1
IGF1R
IGF1R
STAT3
BRCA2
ESR1
BRCA2
STAT3

BRCA2
BRCA2
STAT3
BRCA2
BRCA1
IGFR1
STAT3
STAT3
BRCA2

STAT3
IGF1R
IGF1R
DDB2
FHIT
JAK1
GADD45A
ELK4
CHEK2
NEK2
BARD1
PCNA
TAF10
NEK2
STAT3
ESR1

IGFR1
BRCA1
ESR1
CHEK2
DDB2
ELK1
MAP3K3
TAF10
BCL2
JAK2
CHEK2
BCL2
ELK4
BCL2
TAF10
BRCA1

Two
priors
0.58
0.85
0.72
0.72

Average
prior
0.99
0.96
0.94
0.49
0.43
0.42
0.41
0.40
0.39
0.42
0.41
0.40
0.40
0.41
0.43

DNA
Methylation
0.89
0.89
0.98
0.66
0.40
0.38
0.37
0.41
0.38

Copy
number
0.64
0.89
1
0.40
0.47
0.40
0.44
0.39
0.42
0.40
0.39
0.41

0.38
0.37
0.40
0.36

Supporting Data

Fan et al., 1998
Zhang et al., 2006

Rokavec et al., 2012

Scheidegger et al.,
1999
0.39
0.45

Foulstone et al., 2013

0.83
0.82
0.68
0.68
0.65
0.59
0.55
0.53
0.5
0.45
0.44
0.37
0.43

It is worth to note that EDN1  SERPINF1, and VGLL4  TMEM2 were supported by
all four prior types and could be novel interactions. Although no relationship is known, EDN1 is a
vasoconstrictor and SERPINF1 induces apoptosis by inhibiting stromal vasculature (Doll et al.,
2003). RBMS1 MID2, RBMS1  TFAP2A, and EDN1  FOXA1 were supported by three
prior types.

97
In the BRCA network, there are 17 interactions supported by our results in at least two
prior types. IGF1RSTAT3 interaction, which was supported by three prior types has been
experimentally validated (Zhang et al., 2006). Additionally, IGF1RESR1, BRCA1  BRCA2,
ESR1STAT3, STAT3IGFR1 have supporting evidence (Foulstone et al., 2013; Fan et al.,
1998; Rokavec et al., 2012; Scheidegger et al., 1999). Although there is no validation yet, PCNA
 CHEK2, PCNADDB2 and PCNAJAK1 could be novel interactions as they were assigned
high scores by all prior types.

4.4. Conclusions and future work

We developed an algorithm that scores regulatory interactions based on canonical correlation
analysis (CCA) between various biological datasets and gene expression. We tested our algorithm
on a breast cancer dataset that composed of DNA methylation, copy number and gene expression.
We computed regulatory interactions in three gold standard networks, which were built with
known interactions in HTRI and TRED databases. Our results showed that using DNA
methylation and copy number data as regulator variables performed better than using expression
data as regulator variables. This indicates that DNA methylation and copy number may establish
directionality by distinguishing between regulator and target. These results also highlight the
usefulness of epigenetic and structural information in GRN inference. Some of the CCA
algorithm's top interactions were supported by literature although these interactions did not exist
in the HTRI and TRED databases. These interactions might contain putative regulators controlled
by DNA methylation or copy number changes, and their targets.
We used the results of our CCA algorithm as a prior for a dynamic Bayesian network
(DBN) approach. We ran the DBN algorithm by utilizing DNA methylation- and copy numberbased priors individually and simultaneously. We showed that additional improvements could be
gleaned from using this method over the CCA alone. Like in the CCA algorithm results, some of
the top interactions computed by the DBN algorithm did not exist in the HTRI and TRED
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databases, but supported by recent literature. This suggests that some of the other false positives
that were supported by multiple DBN experiments could be novel interactions. In the absence of a
gold standard, comparing false positives from different priors may reveal potential new
interactions.
Due to the performance of DNA methylation in this study, future work should be geared
towards using this data type to improve regulatory network inference in humans. If DNA
methylation is highly correlated with a gene’s expression, it may be useful to use that information
to detect downstream targets. Other sources of epigenetic or structural data should also be studied
for this potential use.
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CHAPTER 5

CARMMA: A computational pipeline to detect cancer-related miRNA-gene modules and
associated disrupted biological processes

This chapter is a draft of a manuscript which will be submitted to a yet to be determined
journal/conference. Some of the results are preliminary and future work is listed in Future Work
section.
Abstract: microRNAs (miRNAs) regulate the expression of target genes by degradation of
mRNA transcripts or repression of translation. Key miRNAs are dysregulated in cancer and can
therefore disrupt important biological processes, such as cell cycle or apoptosis. Previous studies
have proposed methods to uncover cancer-related miRNA-gene modules based on the
relationship between miRNA expression and gene expression. In this study, we propose
CARMMA, a computational pipeline to detect cancer-related miRNAs that are associated with
target genes via disrupted biological processes and expression data. We applied CARMMA to
luminal A breast and bladder cancer datasets from the TCGA Project. We found that the miRNAgene modules formed by CARMMA are enriched in known interactions from the miRWalk
database. Additionally, the miRNAs selected by CARMMA are enriched in known cancer-related
miRNAs. We also examined the relationship between the expression of selected miRNAs and
new tumor events after initial treatment. Overall, our results suggest that forming miRNA-gene
modules based on biological processes can uncover important miRNAs in cancer.

5.1. Introduction

microRNAs (miRNAs) are short, non-coding molecules of RNA (Ambros, 2004).
miRNAs decrease gene expression by destabilizing or cleaving mRNA transcripts or repressing
translation (Lima et al., 2011). The expression of certain key miRNAs is known to be altered in
cancer cells (Lu et al., 2005). Furthermore, miRNAs dysregulate many processes in cancer and
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are frequently located at fragile sites in genomic regions involved in cancer (Lima et al., 2011;
Calin et al., 2004).
To elucidate the role of miRNAs in cancer, several tools have been developed to detect
cancer related miRNAs and their associated target genes. Karim et al. outlined a methodology to
infer miRNA-gene modules through collective group relationships (Karim et al., 2016). This
methodology grouped miRNAs with similar targets and genes targeted by similar miRNAs and
then established relationships between groups of miRNAs and groups of genes through canonical
correlation analysis. Due to the heterogeneity of cancer, Jin and Lee proposed a biclustering
approach to uncover gene-sample modules and then utilized a Bayesian network approach to
connect candidate miRNAs to the genes in the gene-sample module (Jin and Lee, 2015).
However, these studies do not consider biological processes when building the modules
of miRNAs and target genes. Certain biological processes are known to be dysregulated in cancer
tumors via miRNAs, such as apoptosis (Lima et al., 2011) and cell cycle (Kim et al., 2009).
Therefore, cancer-related miRNAs are more likely to target certain processes. Integrating
information about disrupted processes could aid in elucidating the role of a particular miRNA in
cancer.
In this study, we developed CARMMA, a tool that detects driver miRNAs, associated
targets and disrupted biological processes. To our knowledge, CARMMA is the first tool that
builds cancer-related miRNA-gene modules based on disrupted biological processes. The
differentially expressed miRNAs are associated with biological process GO terms through the
differentially expressed mRNAs. Modules are built based on the associated terms, and then
refined by a LASSO-based method and binding site sequence information. We demonstrate that
the modules found by CARMMA are enriched in interactions between the miRNAs and genes.
Additionally, we show that the miRNAs detected by CARMMA are enriched for known cancerrelated miRNAs. Finally, we examine the relationship between the expression of miRNAs
detected by CARMMA and new tumor events after initial treatment using survival analysis. The
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survival analysis implicated two miRNAs selected by CARMMA, hsa-mir-185 and hsa-mir-141
as potential tumor suppressors in bladder cancer.

5.2. Methods

CARMMA is a tool to detect cancer-related miRNA-mRNA modules, along with
associated disrupted biological processes. First, differentially expressed miRNAs are associated
with GO biological process terms based on their relationship with differentially expressed genes.
Next, preliminary modules of miRNAs and potential target genes are formed based on the
associated biological processes. Finally, each module is refined to select candidate cancer-related
miRNAs and target genes.

5.2.1. Data pre-processing and normalization

The scaling factors for the library sizes that minimize the log-fold changes between
samples were computed using the trimmed-mean of M (TMM) values between each pair of
samples in the edgeR package (Robinson et al., 2010). After accounting for the compositional
biases between libraries with TMM normalization, the log counts per million (cpm) was used for
expression in subsequent analysis, except for differential expression analysis.
DESeq2 was used to determine miRNAs and genes that are differentially expressed in
normal versus cancer samples on miRNA-Seq and RNA-Seq raw counts, respectively (Love et
al., 2014). A gene was considered differentially expressed if the adjusted p-value was < 0.001. A
miRNA was considered differentially expressed if the adjusted p-value was < 0.0001.

5.2.2. GO term association step

In the following steps, we used the log(cpm) after TMM normalization for expression
values. For each differentially expressed miRNA, we computed the correlation between the
miRNA expression and the expression of each differentially expressed gene. This vector was used
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as a score for in a Kolmorgorov-Smirnov (KS) test to determine significant GO terms using the
topGO package in R (Alexa and Rahnenfuhrer, 2016). Since miRNAs generally decrease gene
expression, the KS test determined whether genes annotated with a particular GO term were more
negatively associated with the miRNA. By this approach, differentially expressed miRNAs were
associated with up to ten biological process GO terms through the differentially expressed genes.
We clustered semantically similar GO terms associated with the miRNAs as previously
described for ProcessDriver (Section 3.2.1.2A). For each GO term cluster, we defined GO term
module as the collection of differentially expressed miRNAs that were significantly associated
with at least one GO term in that GO term cluster, and the differentially expressed genes that
were annotated with at least one GO term in that GO term cluster.

5.2.3. GO term module refinement step

For each GO term module with m significantly associated miRNAs and n annotated
genes, we computed a LASSO regression n times using the glmnet package in R (Friedman et al.,
2010), each time with a different gene expression as a response and all of the m miRNAs in the
GO term module as predictors (Algorithm 5.1). The value of λ that produced the sparest model in
which the cross-validation error was within one standard error of the minimum error was used.
For each miRNA, we computed numTS, the number of times the miRNA was selected in the n
instances of LASSO. miRNAs that were in the top 80th percentile of all the m numTS values were
considered further.
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Algorithm 5.1. Module refinement step of CARMMA
Input:
For k GO term modules
Matrices of gene expression for genes in each module 𝑌1 , … , 𝑌𝑘
Matrices of miRNA expression for miRNAs in each module 𝑋1 , … , 𝑋𝑘
1. For i=1:k:
2.
𝑌𝑖 = {𝑦1 , … , 𝑦𝑛 } gene expression associated with module i with n genes
3.
𝑋𝑖 = {𝑥1 , … , 𝑥𝑚 } miRNA expression associated with module i with m miRNAs
4.
𝑛𝑢𝑚𝑇𝑆 = 𝑧𝑒𝑟𝑜𝑠(𝑚)
5.
For j=1:n
6.
Compute LASSO regression with 𝑦𝑗 as a response and 𝑋𝑖 as predictors
7.
For selected miRNA(s) P, 𝑛𝑢𝑚𝑇𝑆𝑃 = 𝑛𝑢𝑚𝑇𝑆𝑃 + 1
8.
End for
9.
Select s miRNAs in the top 80th percentile of numTS
10.
For q=1:s:
11.
Find binding sites in the 3’ UTR of the genes miRNA q was selected for
12.
in steps 5-7
13.
Targets: genes miRNA q was selected for with binding sites for
14.
miRNA q in the 3’ UTR
15.
if length(Targets) > 50:
16.
Report miRNA q and Targets in module
17.
End if
18.
End for
19. End for

Next, for each of the s remaining miRNAs, we determined whether the genes that
miRNA was selected for had binding sites in the 3’ UTR. We downloaded 3’ UTR sequences
from BioMart (Dunrinck et al., 2009) and miRNA seed sequences from miRBase (Kozomara and
Griffiths-Jones, 2014). We determined miRNA target sites in the 3’ UTRs using miRanda with an
alignment threshold score of 130 (Enright et al., 2003). The number of targets associated with a
miRNA is an important indicator of whether the miRNA is cancer-related (Jin and Lee, 2016).
Therefore, if there were more than 50 genes that the miRNA was selected for in LASSO with a
binding site in the 3’ UTR, the miRNA is part of the module and the more than 50 genes are its
targets.
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5.2.4. Data

We applied CARMMA to Illumina HiSeq 2000 RNA sequencing and miRNA sequencing data
for 92 luminal A breast cancer samples and 118 bladder cancer samples from the TCGA database.

5.3. Results

5.3.1. GO term modules are enriched for known interactions

In bladder cancer, CARMMA created 21 GO term modules. After GO term module
refinement step, four of the 21 modules did not select a miRNA, and were therefore discarded. In
luminal A breast cancer, CARMMA created 20 modules and two of the 20 modules did not select
a miRNA. Therefore, there were 17 and 18 modules for breast and bladder cancer, respectively
(Tables 5.1 and 5.2).
We obtained experimentally validated interactions between differentially expressed
miRNAs and differentially expressed genes from the miRWalk 2.0 database (Dweep et al., 2015).
For each GO term module, we computed a p-value for the enrichment of interactions between the
selected miRNAs and genes. This was determined by randomly resampling differentially
expressed miRNAs and genes 1000 times, equal to the number of miRNA and genes that were
selected in the module, and calculating the number of known interactions each time.
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Table 5.1. Enrichment of interactions for GO term modules in bladder cancer. The number
of genes and number of miRNAs are included for each module, as well as the number of
experimentally validated interactions in the miRWalk database. For each module, the p-value
associated with the number of interactions in the miRWalk database was computed by resampling
the same number of miRNA and genes in the module 1000 times.
GO Terms

Number of
miRNAs

Number of
genes

p-value

386

Number of
interaction
s in
miRWalk
63

mitotic nuclear division, cell division,
nuclear division, organelle fission,
chromosome organization, organelle
organization
cell cycle process, cell cycle, mitotic cell
cycle
cell communication, signaling, signal
transduction, cell surface receptor signaling
pathway
single organism signaling

7

2

215

13

0.074

18

674

349

0.001

single-multicellular organism process

18

656

324

0

19

762

334

0.002

multicellular organismal process

19

771

334

0.004

system process, muscle system process,
muscle contraction
regulation of multicellular organismal
process
system development, anatomical structure
morphogenesis, developmental process,
multicellular organismal development,
neuron differentiation, anatomical structure
development, generation of neurons
response to stimulus, cellular response to
stimulus
biological adhesion, cell adhesion

8

195

38

0.044

11

290

113

0.001

7

618

121

0.014

7

815

115

0.082

4

110

9

0.164

DNA replication, translational elongation,
regulation of nucleobase-containing
compound, DNA metabolic process
mitotic cell cycle process

2

396

27

0.048

2

134

9

0.058

biological regulation, regulation of cellular
process, regulation of biological process
cell cycle phase transition

2

220

15

0.045

2

92

9

0.02

single-organism developmental process

1

76

0

1

muscle structure development

1

90

1

0.51

0.050
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Table 5.2. Enrichment of interactions for GO term modules in luminal A breast cancer. The
number of genes and number of miRNAs are included for each module, as well as the number of
experimentally validated interactions in the miRWalk database. For each module, the p-value
associated with the number of interactions in the miRWalk database was computed by resampling
the same number of miRNA and genes in the module 1000 times.
GO terms

Number of
miRNAs

Number of
genes

mitotic cell cycle process

6

144

Number of
interactions
in
miRWalk
22

p-value

cell cycle process, cell cycle, mitotic cell
cycle
mitotic nuclear division, organelle fission,
organelle organization, nuclear division,
cell division
DNA metabolic process

11

267

70

0.042
0.032

14

471

120

0.074

7

121

21

single-multicellular organism process

14

1113

240

multicellular organismal process

14

1135

221

system process, neurological system
process
signaling, cell communication, signal
transduction, cell surface receptor
signaling pathway, G-protein coupled
receptor signaling pathway
single organism signaling

14

323

54

0.043
0.115
0.119
0.155

12

975

181

0.101

12

968

185

response to stimulus, cellular response to
stimulus
developmental process, multicellular
organismal development, anatomical
structure development, system
development, cardiovascular system
development, circulatory system
development, vasculature development,
blood vessel development, tissue
development, organ development
single-organism developmental process

11

1275

219

0.084
0.092

11

930

156

0.082

7

895

96

cellular response to DNA damage
stimulus
regulation of multicellular organismal
process
regulation of developmental process

1

58

0

0.077
1

6

410

43

0.061

1

224

21

biological regulation

1

1094

0

single-organism organelle organization

1

209

2

mitotic cell cycle phase transition

1

61

0

0.004
1
0.438
1
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5.3.2. CARMMA miRNAs are enriched for known cancer-related miRNAs

To assess whether the miRNAs selected in the GO term modules were more cancerrelated than those that were not, we downloaded disease-associated miRNAs from the Human
MicroRNA Disease Database (HMDD) and searched for miRNAs that were associated with
neoplasms (Li et al., 2013). In bladder cancer, 33/43 (77%) of the selected miRNAs were
associated with neoplasms as opposed to 58% (60/104) of the differentially expressed, but nonselected miRNAs. In breast cancer, 32 out of 36 (89%) of the selected miRNAs are associated
with neoplasms in the HMDD database, as opposed to 43 out of 97 (42%) of the differentially
expressed, non-selected miRNAs (Table 5.3). We also investigated more specific neoplasmassociations, breast and urinary bladder neoplasms. In luminal A breast cancer, there was a much
higher percentage (24/36) of the miRNAs selected in GO term modules that were associated with
breast neoplasms compared to differentially expressed miRNAs that were not selected (20/97).
By randomly resampling 36 miRNAs from the 133 differentially expressed miRNAs 10,000
times, the p-value associated with selecting 24 or more breast neoplasm-associated miRNAs is 0.
Using the same re-sampling technique, we calculated the p-value for neoplasm-associated
miRNAs in breast and bladder cancer, and urinary bladder neoplasms in bladder cancer. The
results are summarized in Table 5.3.
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Table 5.3. Number of cancer-associated miRNAs that were selected in GO term modules by
CARMMA versus not selected. For miRNAs that are selected in GO term modules, the
percentage indicates the number of selected miRNAs that are associated with cancer in the
respective database over the total number of miRNAs that were selected. A p-value for this
percentage was determined by randomly resampling the number of selected miRNAs from the
total number of differentially expressed miRNAs. For miRNAs that are not selected, the
percentage indicates the total number of non-selected miRNAs associated with cancer in the
respective database over the total number of non-selected miRNAs.
Bladder cancer
Luminal A breast cancer

Neoplasms
(HMDD)
Urinary
bladder
neoplasms
(HMDD)
miRCancer
database

Selected in
modules with pvalue
33/43
0.02
(77%)

Not
selected

Selected in
modules with pvalue
32/36
0
(89%)

Not
selected

60/104
(58%)

Neoplasms
(HMDD)

13/43
(30%)

0.135

21/104
(20%)

Breast
neoplasms
(HMDD)

24/36
(67%)

0

20/97
(21%)

16/43
(37%)

0.17

29/104
(27%)

miRCancer
database

16/36
(44%)

0.03

24/97
(25%)

43/97
(42%)

We also downloaded cancer-related miRNAs from the miRCancer database (Xie et al.,
2013). In bladder cancer, we found a higher percentage of miRNAs in the miRCancer database
for the miRNAs that were selected in GO term modules versus the differentially expressed
miRNAs that were not selected in both breast and bladder cancer (Table 5.3). A summary of the
number of articles found in both the HMDD and miRCancer database for the selected miRNAs
are presented in Tables 5.4 and 5.5.
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Table 5.4. Number of articles in the HMDD and miRCancer database for selected miRNAs
in bladder cancer. Number of unique articles for each miRNA that associate the miRNA with
cancer in both of the databases.
miRNA
miRCancer
HMDD
miRNA
miRCancer
HMDD
hsa-mir-21
0
93
hsa-mir-185
0
2
hsa-mir-143
0
34
hsa-mir-147b
0
2
hsa-let-7c
20
23
hsa-mir-28
0
1
hsa-mir-17
0
23
hsa-mir-33a
0
1
hsa-mir-205
0
22
hsa-mir-455
4
1
hsa-mir-92a-1 0
18
hsa-mir-942
1
1
hsa-mir-210
0
17
hsa-mir-944
3
1
hsa-mir-18a
0
14
hsa-mir-345
0
1
hsa-mir-141
20
13
hsa-mir-33b
0
1
hsa-mir-183
0
10
hsa-mir-454
7
1
hsa-mir-19a
29
10
hsa-mir-584
1
1
hsa-mir-135b
15
10
hsa-mir-548ba 0
0
hsa-mir-218-1 0
9
hsa-mir-3934
0
0
hsa-mir-96
28
8
hsa-mir-4652
0
0
hsa-mir-106b
0
7
hsa-mir-4746
0
0
hsa-mir-204
0
7
hsa-mir-671
2
0
hsa-mir-195
0
6
hsa-mir-1307
0
0
hsa-mir-139
18
5
hsa-mir-940
5
0
hsa-mir-23b
0
5
hsa-mir-4664
0
0
hsa-mir-30a
27
4
hsa-mir-1247
0
0
hsa-mir-130b
0
3
hsa-mir-504
2
0
hsa-mir-301b
5
3
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Table 5.5. Number of articles in the HMDD and miRCancer database for selected miRNAs
in breast cancer. Number of unique articles for each miRNA that associate the miRNA with
cancer in both of the databases.
miRNA
miRCancer HMDD
miRNA
miRCancer
HMDD
hsa-mir-21
0
93
hsa-mir-378a
0
5
hsa-mir-145
0
55
hsa-mir-342
0
5
hsa-mir-125b-1 0
26
hsa-mir-486
8
4
hsa-mir-200b
11
23
hsa-mir-497
32
4
hsa-mir-200a
21
21
hsa-mir-193a
0
3
hsa-mir-210
0
17
hsa-mir-129-1
0
3
hsa-mir-10b
0
15
hsa-mir-495
11
3
hsa-mir-141
20
13
hsa-mir-452
7
2
hsa-mir-182
0
12
hsa-mir-337
4
2
hsa-mir-29a
0
11
hsa-mir-148b
0
2
hsa-mir-183
0
10
hsa-mir-488
2
2
hsa-mir-429
8
9
hsa-mir-584
1
1
hsa-mir-218-2
0
8
hsa-mir-33b
0
1
hsa-mir-96
28
8
hsa-mir-381
0
1
hsa-mir-140
16
7
hsa-mir-190b
0
0
hsa-mir-204
0
7
hsa-mir-374c
0
0
hsa-mir-32
10
6
hsa-mir-592
4
0
hsa-mir-139
18
5
hsa-mir-203a
0
0

5.3.3. miRNAs selected by CARMMA are related to new tumor events after initial
treatment

miRNAs that promote tumorigenesis may have metastatic properties (Pencheva and
Tavazoie, 2013). We examined the relationship between the number of days to new tumor events
after initial treatment and the expression of the selected miRNAs in bladder cancer. We
discretized the miRNA expression into up/down expressed tumor samples using a log 1.2-foldchange over the median expression value. Baseline samples were removed from the analysis. We
then created Kaplan-Meier (KM) plots and looked for significant differences in the number of
days to new tumor events after initial treatment between up and down expressed samples. Ninetyfive patients in the bladder cancer cohort experienced a new tumor event after initial treatment.
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Only 2 of the 92 luminal A breast cancer patients experienced new tumor events, therefore we
applied this analysis to bladder cancer data only.
We found that miRNA hsa-mir-185 had the most significant difference between the
number of days to new tumor event of up and down expressed samples (p = 0.00013). hsa-mir185 has been implicated as a tumor suppressor in multiple studies across multiple cancers, but not
bladder cancer. Specifically, it is linked to cell cycle arrest in lung cancers and inhibition of
proliferation in colorectal cells (Takahashi et al., 2009; Liu et al., 2011). Additionally, we found a
significant difference in the number of days to new tumor events between up and down expressed
levels of hsa-mir-141 (p = 0.01). This miRNA inhibits pancreatic cancer cell invasion and
migration (Xu et al., 2014; Wang et al., 2015). These results suggest that these two miRNAs are
good candidate tumor suppressor miRNAs in bladder cancer.

Figure 5.1. Kaplan-Meier plots for the number of days to new tumor events after initial
treatment versus miRNA expression

5.4. Conclusions and future work

We designed and implemented CARMMA, a tool to detect cancer-associated miRNA,
targets and disrupted biological processes. We applied CARMMA to luminal A breast cancer and
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bladder cancer datasets from the TCGA database. To our knowledge, CARMMA is the first
algorithm to build miRNA-gene modules based on biological processes. We found that the GO
term modules produced by CARMMA are enriched in known interactions between the miRNAs
and genes. We also found that the miRNAs selected by CARMMA are enriched in known cancerassociated miRNAs.
Our results based on survival analysis indicate potential miRNA biomarker for bladder
cancer. Particularly, given its tumor suppressor activities in other cancers, hsa-mir-185 is a
potential biomarker for bladder cancer. Additionally, hsa-mir-141 is another potentially novel
biomarker for bladder cancer. Based on the relationship with the number of days to new tumor
events, both miRNAs can be investigated for tumor suppressor activities in bladder cancer.
Overall, these preliminary results highlight the potential value of creating modules based
on biological processes. This can aid in elucidating the potential process(es) that a miRNA
disrupts in cancer. In the future, we plan to integrate DNA methylation and copy number data
such that the relationship between miRNA and gene expression cannot be confounded by these
factors. Additionally, we will compare CARMMA to previously published methods to determine
the overall improvement of this method over other cancer-related miRNA-gene module detection
methods.
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CHAPTER 6
Conclusions and future work
This dissertation presented four tools that integrate multiple types of biological data to
gain meaningful insights about the genes, miRNAs and interactions involved in cancer. Much of
the focus has been on interactions between regulatory genes, miRNAs and associated downstream
target genes. Previous work treated structural and epigenetic effects as confounding factors when
examining relationships between regulatory genes, miRNAs and target genes. This dissertation
examines the utility of structural and epigenetic information to aid in proposing candidate cancer
driver genes and miRNAs, as well as their interactions. Particularly, Chapter 3 examined finding
driver, regulatory genes within a copy number aberration and Chapter 4 examined leveraging
structural and epigenetic states of regulators to establish relationships with targets.

6.1. Contributions of dissertation

The four tools developed in this dissertation may be useful towards future research. Our
paper on selecting DNA methylation probes that are most predictive of gene expression can be
useful to researchers who are working with 450K DNA methylation data (Chapter 2). Since there
is an average of ~18 probes per gene, choosing the probe(s) that best represent the overall DNA
methylation is important for downstream functional analysis. Some of the previous studies
focused on only probes in upstream regions, which may ignore functionally important DNA
methylation from the gene body (Farré et al, 2015; Rica et al., 2013). Furthermore, some studies
did not consider gene expression when choosing which DNA methylation probes to study
(Selamat et al., 2012; Noushmehr et al., 2010). In this work, we provided a comprehensive
analysis of feature selection and classification methods for selecting the DNA methylation
probe(s) that are most predictive of gene expression.
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Since the algorithm was developed, the Infinium MethylationEPIC BeadChip microarray,
covering 850,000 CpG methylation sites was developed (Moran et al., 2016). Since the
sequential-forward selection with K-nearest neighbors algorithm is computationally inexpensive
and the 850K array is similar to the 450K array, we hope that as data for the 850K arrays
becomes available, this algorithm will be successful.
ProcessDriver was developed to compute candidate copy number based cancer driver
genes, potential targets and associated biological processes (Chapter 3). We applied
ProcessDriver to three cancer types and found that the drivers that were uncovered were enriched
in known cancer genes. We also found that the drivers were associated with new tumor events
using survival analysis. Aure et al. associated drivers with biological processes, but also used the
correlation of copy number to cis gene expression to narrow down drivers (Aure et al., 2012).
Other methods utilize the relationship of cis gene expression to trans gene expression to create
modules of driver genes and associated targets, but do not use biological process information
(Akavia et al., 2010). ProcessDriver’s unique methodology builds modules based on biological
processes and then narrows down drivers based on the relationship of cis gene expression to trans
gene expression. In this work, we also demonstrated the value of utilizing the relationship
between cis gene expression and trans gene expression to uncover drivers, as opposed to previous
approaches that select the cis genes that are most correlated to their own copy number.
Our CCA/DBN algorithm demonstrated that structural and epigenetic aberrations can be
leveraged to infer regulatory interactions, as opposed to being treated as a confounding factor
(Chapter 4). In particular, leveraging DNA methylation states for regulators leads to an increased
accuracy in the prediction of regulatory interactions, as opposed to using copy number or gene
expression states for regulators. This methodology is unique because previous methodologies
have mainly focused on the relationship between regulatory gene expression and target gene
expression. In particular, the use of structural and epigenetic states for regulators should be
examined in terms of its ability to establish directionality in a directed network.
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In Chapter 5, we described our ongoing work to develop CARMMA, a tool to build
miRNA-gene modules based on biological processes, allowing for additional insight into the
processes a miRNA can disrupt. Our preliminary results propose some candidate cancerassociated miRNAs in bladder cancer, based on previous literature from other cancers and
survival analysis. These and other miRNAs uncovered by CARMMA may be valuable to future
research and could be therapeutic targets for future cancer drugs.

6.2. Future directions

As technology in biology develops, so does the need for computational tools that can
integrate multiple types of biological data and aid in making meaningful insights. Due to the scale
of the data available, genome-wide approaches are becoming more useful in prioritizing
regulatory miRNA and genes of interest to cancer. Both of the most recent tools in this
dissertation, ProcessDriver and CARMMA, take a genome-wide approach. However, the nuance
of pin-pointing exact interactions between miRNAs or genes, as in the DBN approach, gets lost in
these genome-wide approaches. Therefore, much of the future work should be geared towards
also prioritizing cancer-related interactions genome-wide that have a greater chance of being
accurate when experimentally validated.
It was noted in the dissertation that genes that are predicted well by DNA methylation are
enriched in regulatory biological processes (Chapter 2). Additionally, utilizing DNA methylation
for potential regulators achieved high accuracy in the CCA/DBN approach (Chapter 4). This
suggests that genes controlled by DNA methylation may regulate many target genes in cancer.
Therefore, the concept of epigenetic drivers should be examined further.
Most of the data used in this work was from the TCGA repository. These samples are
composed of heterogeneous cell populations, and therefore may have various hidden confounding
factors. In fact, many of these technologies rely on bulk RNA and DNA which only provides
information about the average state of the cells present (Navin and Hicks, 2011). Solid tumors
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contain non-cancerous cells such as fibroblasts, lymphocytes and macrophages (Navin and Hicks,
2011). Furthermore, solid tumors could contain multiple clonal subtypes which implies that if
multiple clones are present in a tumor, the data obtained is the average or more representative of
the more dominant clone, which also may not be the most malignant (Navin and Hicks, 2011).
These multiple clones could confound analysis. Therefore, one exciting new area of
research is in single cell sequencing. DNA sequencing technology has advanced to the point
where little DNA is required, making it more feasible to analyze the DNA of single cells (Shapiro
et al., 2013). Due to this technology, new studies have come out investigating intra tumor genetic
heterogeneity in cancer development and response (Gawad et al., 2016). While the single-cell
sequencing has mostly been limited to probing the transcriptome, a new method, scM&T, has
been developed that performs simultaneous genome-wide sequencing of the transcriptome and
methylome (Koch, 2016).
Single cell sequencing has promise in the field of personalized medicine. For example,
only 5% to 10% of patients with ductal carcinoma in situ (DCIS) progress to an invasive
carcinoma, and studies of DCIS suggests heterogeneity is present in the early stages (Navin and
Hicks, 2011). If it is possible to ascertain the tumor heterogeneity in an individual clinical sample
of a DCIS patient, it is possible to predict if that tumor is likely to become invasive (Navin and
Hicks, 2011).
Additionally, applying copy number driver detection methods to samples of a single cell
type within a tumor type may allow for more targeted therapies. More intensive focus could be
placed on identifying therapeutic target genes (e.g. driver genes) and miRNAs within the more
malignant clonal subtypes, as opposed to using the “averaged-out” bulk RNA and DNA data used
currently. When single cell approaches to uncovering copy number and DNA methylation
become more feasible and widely-adopted, identifying drivers disrupted by a copy number or
DNA methylation change within a particular clonal subtype in a tumor can become possible.
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